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Abstract
HYPOTHALAMIC CIRCUITS MEDIATING CONSUMPTION AND ANXIETY
Ryan Michael Cassidy
Advisory Professor. Qingchun Tong, PhD
From 1960-2016, U.S. obesity prevalence increased 13-40% and diabetes increased
from 3-15%. There is an epidemic of metabesity, the aggregate metabolic disorders
produced by chronic overeating. Drugs for metabesity were developed in the 1930s with
limited effectiveness; agents today rely on the same principles and are similarly
ineffective. Particularly surprising has been the failure of satiety enhancers; this indicates
it may not be that physiologic hunger drives chronic overeating. Although hunger and
satiety affect traditional reward circuitry (Cassidy & Tong 2017), evidence for the primacy
of this effect is mixed. Being hungry reduces anxiety-like behavior in mice; whether the
act of eating also reduces anxiety is not well-known. If true, this represents a different
avenue for the beneficial effects of eating than just reward manipulation or satiation. The
aim of this dissertation is to discover hypothalamic neurocircuits involved in this
relationship.
This body of work is the result of two projects in mice. In the first project, I
demonstrate that GABAergic eating neurons in the lateral hypothalamus (LH) inhibit
GABAergic anxiety neurons in the basal forebrain (BF). Activating this circuit causes
feeding and reduces anxiety; fiber photometry shows LH neurons are active both during
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food approach and food consumption, but BF neurons only drop in activity during eating.
Conversely, BF neurons activate in response to environmental anxiogenic stimuli. It
appears that the act of eating can, through the LH-BF circuit, directly reduce sensitivity to
threatening stimuli The second project is in collaboration with Yuanzhong Xu and
Yungang Lu on a parallel circuit from the paraventricular hypothalamus (PVH)
glutamatergic projections to the ventral lateral septum (LSv) GABA neurons. My work with
fiber photometry shows that both the PVH and LS respond to anxiety-provoking stimuli
and are silenced by food, but with divergent activation/deactivation dynamics.
This data shows at the circuit level that the act of eating itself, not hunger per se,
reduces activity of anxiety regions in the brain via hypothalamic neurocircuits. It may be
that some metabesity arises from chronic overeating of food eaten for anxiolytic
manipulation of these circuits, a concept popularly called "stress eating". Until this
behavior is addressed by new psychotherapy or pharmacology, these patients will likely
struggle to recover.
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Chapter 1. The untreated etiology of metabesity: acute-on-chronic overeating
This chapter represents original review work produced for this dissertation

1

1.1.

The Lost War on Obesity.
Corpulence. Of all the parasites that affect humanity I do not know of, nor
can I imagine, any more distressing that of Obesity [...] Obesity seems to me very
little understood or properly appreciated by the faculty and the public generally, or
the former would long ere this have hit upon the cause for so lamentable a disease,
and applied effective remedies, whilst the latter would have spared their injudicious
indulgence in remarks and sneers [...]
Oh! that the faculty would look deeper into and make themselves better
acquainted with the crying evil of obesity-that dreadful tormenting parasite on
health and comfort. Their fellow men might not descent into early premature
graves [...] from what is termed apoplexy, and certainly would not, during their
sojourn on earth, endure so much bodily and consequently mental infirmity.
-- William Banting, 1863 "A Letter on Corpulence, Addressed to the Public"
Mr. William Banting, an English undertaker, published the first widely popular and

successful dieting book of the modern era 1. He was 66 years old, 5'5 and 202lbs. After
visiting many physicians who recommended exercise or ignored his complaints, he finally
found one Dr. William Harvey (who got the idea from Claude Bernard and bears no
relation to the famous William Harvey of the 17th century who described the circulation
of blood). Dr. Harvey suggested he 1) abstain from beer (but not liquor) and 2) practice
what is recognizable now as a low carbohydrate diet. Banting lost 46lbs over a year and
stayed at his ideal weight afterwards. Because of his struggle to find effective dieting
advice and to find physicians who took his struggles seriously, Banting published this
pamphlet in 1863 and distributed several thousand copies, for free, to the general public.
The pamphlet was so popular that “Banting” became a synonym for dieting for many
years afterwards.

2

Low

carbohydrate

and

ketogenic

diets

like

Banting's

are

the

popular

recommendation du jour for weight loss. Like most popular diets and exercise programs,
they have demonstrable efficacy for weight loss 2. Banting's desire to spread information
has been far exceeded, at least in the U.S., by various governmental agency initiatives
such as: the U.S. Department of Agriculture's Dietary Guidelines for Americans and
ChooseMyPlate.gov; the Centers for Disease Control (CDC) "Healthy Weight" publication
series; the U.S. Public Health Service's Dietitian Professional Advisory Committee's Weight
Management Modules; the National Institute of Diabetes and Digestive and Kidney
Diseases Weight-Control Information Network; the Department of Health and Human
Service's Physical Activity Guidelines for Americans and it's "Healthy People 2020"
initiative; etc 3. These are not new. Such public health initiatives specifically for weight
control have been ongoing since the 1970s and have been termed, in keeping with the
rhetoric of many policy initiatives from that era, "The War on Obesity"

4–9

. However, such

initiatives have been ineffective: the prevalence of obesity and type 2 diabetes mellitus
(T2DM) have tripled since such statistics were first recorded on a national level. These
trends are depicted in Figure 1 10–15.

3

Figure 1. Metabesity prevalence in the U.S. over time
Data integrated from multiple different Centers for Disease Control (CDC), National
Health Examination Survey (NHES) and National Health and Nutrition Examination Survey
(NHANES), reports on population prevalence estimates of each disease

. Includes adults

10–15

over the age of 18, both sexes. Current guideline recommendations for threshold values for
hypercholesterolemia, hypertension, and hyperglycemia/%HbA1C were used for historical
values, as discussed in the references.

4

The sobering reality of these data is not meant as a repudiation of these
initiatives. The great triumph of behavioral interventions in public health is the concurrent
dramatic reduction in smoking also seen in Figure 1. Beyond the deleterious effects of tar
and particle inhalation on the lung causing inflammation, chronic obstructive pulmonary
disease, and lung cancer, smoking also directly contributes to metabolic disease because
chronic nicotine ingestion independently induces hypertension, hypercholesterolemia,
and insulin resistance

16–19

. Yet, despite halving the prevalence of smoking, these chronic

diseases are relentlessly increasing in prevalence. At the surface level, it appears that the
intervening 150 years since Banting's publication have not produced any meaningfully
more efficacious advice or information on how to control weight. Indeed, although they
all can produce dramatic changes in weight, the factors that determine whether any
particular individual will respond remain unknown. It seems that knowledge of effective
diets is necessary, but not sufficient to stem the epidemic of obesity.
In order to progress beyond Banting, it is thus necessary to revisit the
pathophysiology leading to weight gain and metabolic disease. As will be described below
in detail, obesity and metabolic disease are multi-factorial and thus many different
therapeutic approaches have been implemented. One crucial driver of obesity and
metabolic disease is overeating. Although satiety agents have been developed to curb
hunger and prevent overeating, their success has been limited. The possibility that some
eating behavior is not driven by physiologic hunger has not been examined in detail. One
reason that this may have been relatively understudied is the diverse nature of research
5

on eating behavior, obesity, and metabolic diseases. Thus, the goal of this chapter is also
to integrate findings from each of these fields into a unified story and demonstrate the
key role of non-physiologically driven eating behavior within it.

1.1.1. Metabesity and weight loss: useful short-hand
Before discussing the potential causes of obesity and metabolic diseases, the
disease state itself must be defined. There are a variety of terms used to describe the
cluster of chronic diseases believed to be of metabolic origin such as metabolic
syndrome, metabolic disease, diabesity. For the purposes of simplicity, I will use the
neologism metabesity, discussed in greater detail in section 1.2. It is a broad term, first
coined by the endocrinologist Alexander Fleming in the early 2010s, meant to link a
diverse set of chronic diseases that share a common metabolic etiology driven at least in
part by the environment, rather than pure genetic concerns

20,21

. The biomarkers of

obesity, hypertension, hypercholesterolemia, hypertriglyceridemia, hyperglycemia and
T2DM and chronic inflammation are all included within metabesity, as are their diverse
sequelae such as atherosclerosis and microvascular complications of advanced glycation
end-products

. Given that obesity and other metabolic illnesses are interrelated and

21

tightly associated with weight gain and that weight loss - or at least reduction in calories improves all of them (section 1.2), I will also use the short-hand of weight loss to refer to
recovery from metabesity.
The increase in the prevalence of metabesity cannot be primarily attributed
to an aging population nor to older adults who quit smoking and thus lost the hunger6

suppression mediated by nicotine

22,23

. The percentage of children aged 6-11 years old

with metabesity has increased at the same rate, if not faster. For example, in 1965, an
estimated 4.2% of this group was obese; in 2016, 18.4% were obese

11,24

. Around the

1990s, endocrinologists stopped referring to T2DM as adult-onset diabetes, because so
many children were being diagnosed with it that childhood onset of hyperglycemia was
no longer pathognomonic for autoimmune diabetes (type 1). Now, nearly half of all
children (<18 years old) diagnosed with diabetes have T2DM, rather than T1DM

25

. Such

trends are worldwide 5.
Nor can the lack of progress in treating metabesity be attributed to a lack of
advancement in medical therapy. A person with an acute myocardial infarction was twice
as likely to die in the hospital or 1 month after discharge in 1960 than in 1990

26

. The

pharmacotherapy available for management of metabesity has similarly expanded
considerably. The majority of drugs approved by Food and Drug Administration (FDA)
target metabolic illness are, in fact, either 'me too' drugs with pharmacokinetics
optimized for certain patient subsets, or drugs targeting the same disease via a different
mechanism

27

. There has even been substantial legislation-driven intervention in the

pharmaceutical market attempting to promote development of new and less costly drugs
to try and maximize access 28,29.
Even if the rise in biomarkers of metabesity was inevitable, many experts predicted
that the development of newer and better treatments will reduce morbidity, mortality,
and ultimately cost of care for the manifestations of metabesity

30

. This has not been the
7

case; morbidity and costs have only increased

31

. The burden of metabesity may even

have stymied the expected growth in life expectancy in the early 21st century. It is
disappointing to compare historical estimations of what the average lifespan of a 65 year
old woman would be in 2000 to what they actually became

32

: in 1981, 1984, 1995, and

2000, the estimated remaining years of life were 21, 20.5, 19, and 18.5, respectively.
Although much attention has been paid in recent years to the decline in life span
attributable to drug overdoses and suicide in people aged 55-64y since the 2010s, it is
also true that metabesity-linked deaths are also increasing. In fact, the increase in deaths
attributed to heart disease has risen at the nearly same rate as drug overdose since 2011
33

. In general, the majority of the top ten causes of death in 2017 as reported by the CDC

share some or all origin in metabesity 34.
The diverse set of diseases encapsulated by metabesity have all risen in
prevalence, indicating a common connecting etiological factor. In my view, as I will
elaborate in section 1.2.1 and 1.2.2, metabesity is driven by overeating and subsequent
weight gain. However, because the concept of obesity has intersected with social forces
interested in reducing guilt and shame for body type, and that obesity is usually the only
disease readily connected to overeating, this connection has often been neglected or
misinterpreted. For example, a short missive from Medscape in 2006 titled "End the War
on Obesity: Make Peace with Your Patients" makes the following claims

35

: weight has been

greatly exaggerated as a health risk; sustained weight loss is not practical nor wellestablished to improve health; health-improvements arise from health behaviors
8

regardless of loss of fat mass. While I agree with this to some extent, as I will argue in
1.2.2, sustaining healthy behaviors that improve health should inherently result in weight
loss. This article is emblematic of some of the confusion that must be resolved on the
pathophysiology and etiology of metabesity.The sobering reality of these data is not
meant as a repudiation of these initiatives. The great triumph of behavioral interventions
in public health is the concurrent dramatic reduction in smoking also seen in Figure 1.
Beyond the deleterious effects of tar and particle inhalation on the lung causing
inflammation, chronic obstructive pulmonary disease, and lung cancer, smoking also
directly

contributes

to

metabolic

disease

because

chronic

nicotine

ingestion

independently induces hypertension, hypercholesterolemia, and insulin resistance

16–19

.

Yet, despite halving the prevalence of smoking, these chronic diseases are relentlessly
increasing in prevalence. At the surface level, it appears that the intervening 150 years
since Banting's publication have not produced any meaningfully more efficacious advice
or information on how to control weight. Indeed, although they all can produce dramatic
changes in weight, the factors that determine whether any particular individual will
respond remain unknown. It seems that knowledge of effective diets is necessary, but not
sufficient to stem the epidemic of obesity.

9

1.2.

Overeating produces metabesity
To determine the necessary etiologies of metabesity, it is important to first set the

definition. I specifically have used metabesity (section 1.1.1) to emphasize the common
origin of multiple chronic diseases; this term, though a bit clunky, is an encompassing
categorizer that has at least some nomenclature distinctness from traditional descriptors
of metabolic disease. This concept owes its origin to metabolic syndrome (MetS). MetS ,
described below, refers to the finding that there is a greater-than-chance clustering of
elevated biomarkers for several chronic diseases in a given individual – this has
subsequently been attributed to insulin resistance. MetS has been well-studied clinically,
and the influence of short-term changes in behavior has a surprisingly profound effect on
it’s constituent biomarkers. In particular, there have been a series of rigorous studies on
the effects of short-term fasting on biomarkers of MetS. In their totality, these studies
demonstrate both the utility of the term metabesity and of the behaviors that lead to its
manifestation – overeating.

1.2.1. The metabolic syndrome and "metabolic healthy" obesity
The metabolic syndrome (MetS) otherwise known as syndrome X, insulin resistance
syndrome, cardiometabolic syndrome, or Reaven's syndrome, is an anchoring concept
created to understand the correlation of various metabolic diseases together

36–38

.

Specifically, it refers to a cluster of clinical findings - central adiposity (usually measured
by waist circumference, though imaging now is more specific and can identify visceral
adipose tissue instead), hypertension, insulin resistance, and atherosclerotic biomarkers
10

like dyslipidemia with elevated low-density lipoprotein to high density lipoprotein ratio
LDL/HDL. The 2016 NHANES survey estimates that up to 35% of adults in the U.S. have
MetS 14. The fact that these diseases cluster together indicates that they share a common
etiology.

1.2.1.1.

Healthy at every size?

While insulin resistance is often the proximal culprit of these findings, the origin of
such insulin resistance is murky and often not attributed to obesity. Indeed, a 2014
publication in the American Journal of Public Health titled "Obesity, health at every size, and
public health policy" made the following statement 9:
Obesity is associated with chronic diseases that may negatively affect
individuals’ health and the sustainability of the health care system. Despite
increasing emphasis on obesity as a major health care issue, little progress has
been made in its treatment or prevention [...] Evidence is accumulating that a
weight-neutral, nutrition- and physical activity–based, Health at Every Size (HAES)
approach may be a promising chronic disease-prevention strategy
There is some truth to this; obesity itself (having a high total body weight)
independent of endocrine abnormalities likely only drives accelerated osteoarthritis

39

.

Instead, it is the metabesity associated with excess adiposity that causes chronic disease;
the differentiation is relevant for making decisions about intensiveness of medical
intervention

. However, it seems incorrect that "nutrition and physical activity" can

40

correct MetS without also inherently correcting for the factors leading to the development
of excess adiposity, hence leading to long-term weight loss. This implies that process

11

leading to obesity is not an ongoing process that continues to accumulate metabolic
damage.
Fortunately, some rigorous prospective cohort studies have been conducted to
answer questions like this; the Framingham Heart Study is a classic example, but there
are several others. The specific question as to the temporal relationship between excess
adiposity and future metabesity was evaluated by the CARDIA study

41

. This 30-year

prospective cohort study demonstrated that metabolically healthy obesity (MHO; i.e.
excess adiposity without metabolic disease) is, for most people, a transient stage. After
several years of MHO, most individuals then develop metabesity (defined here as
hypertension, dyslipidemia, or hyperglycemia)

41

. Further, few individuals developed

metabesity without passing through the MHO stage, indicating that obesity may be an
early marker of the metabesity disease process. These findings have been replicated in
several other large scale cohort studies; the more time is spent living with MHO, the
higher the probability of developing metabesity

42–45

. Some public health researchers

question the utility of MHO as a concept entirely 46.

1.2.1.2.

Adiposopathy versus overeating on top of adiposopathy

This raises the next logical question: if obesity almost always precedes metabesity,
is it the excess adiposity itself that drives the elevation of biomarkers? This is sometimes
called adiposopathy or the adiposocentric paradigm

47,48

. The identification of excess

visceral fat as far more predictive of metabesity as compared to subcutaneous fat is an

12

example of the utility of this model. Put another way, the question is this: which of the
following is a more useful generalization of the transition from MHO to metabesity?
Chronic overeating --> adiposopathy --> sustained elevated biomarkers
OR
Chronic overeating --> adiposopathy + acute overeating --> elevated biomarkers
The short-term fasting literature on healthy humans and humans with metabesity
can help differentiate these two conditions. If adiposopathy is the primary driver of
metabesity, a certain amount of weight loss should precede and predict the degree of
recovery in any given biomarker of metabolic illness. Conversely, if acute overeating on
top of these resistance mechanisms causes the elevated biomarkers, short-term fasting
without substantial fat-mass loss should result in meaningful recovery of biomarkers. This
latter behavior can be referred to as acute-on-chronic overeating (ACO). The significance
of this distinction will be discussed after reviewing this evidence.

1.2.2. Short-term fasting dramatically reduces metabesity biomarkers
Short term fasting studies in humans with metabesity are powerful experimental
tools to differentiate whether it is excess adiposopathy or ACO that is the primary driver
of the perpetuation of the biomarkers of metabesity. NOTE: the following is not
demonstrating that fasting is "curative" of the known resistance mechanisms that are related
to adiposopathy. Instead, it is a demonstration that eating excess energy acutely, on top of the
adiposopathy, is what drives the elevated biomarkers known to cause the sequelae of

13

metabesity like coronary artery disease from cholesterol and hyperglycemia. Table 1 is a nonexhaustive summary of the effects of short- and medium-term fasting on relevant
biomarkers of metabesity

49–57

. Further work on the subject of fasting, very low calorie

diets (VLCD) and their effect on metabesity and longevity can be found here 58–66.
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Table 1. Short-term negative energy balance reduces metabesity biomarkers
Data consolidated from sources indicated in the first column. Each value is the
reported mean change from

baseline. - means no value, n.s. means change was not

significant. All lab values were taken in the morning. Units were standardized. Most studies
include men and women. See Abbreviations for acronyms.
Duration
(days)

Method

Andersson
1988

2

VLCD

Browning
2012

2

Water

Chan 2003

3

Felber 1981
Watts 1990
DessiFulgheri
1999
Hall 2015

6

Citation

Jackson
1971
Li 2013

Disease

N

Weight
(kg)

SBP
Glucose TC (mg/ LDL
HDL
TGs
Insulin
Leptin
(mmHg) (mg/dL)
dL)
(mg/dL) (mg/dL) (mg/dL) (uU/mL) (ng/mL)

Obese & HTN

11

-2

-17

-

-

-

-

-

-

-15.5

Healthy (F)

9

-

-

-11

31

-

-

-35

-13

Healthy (M)

9

-

-

-15

11

-

-

-40

-9

-4.1

Water

Healthy

8

-1.8

-

-

-

-

-

-

-4.3

-1.97

3

VLCD

Obese & T2DM

6

-1.5

-

-100

-

-

-

-50

-12

-

3

Water

Obese & T2DM

10

-3.5

-

-138

-

-

-

-

n.s.

-

4

VLCD (+7g
NaCl)

Obese & HTN

8

-2.9

-10.9

-

-

-

-

-

-

-

19

-1.8

-

n.s.

-8

n.s.

-3

-17

-2.8

-3.89

-1.3

-

-7.1

-19

-11

-7

-4

-2

-2.89
-

7
7

Stange
2013

7

Lingvay
2013

10

Goldhamer
2001

10

Goldhamer
2002

-30% carb
-30% fat

Obese
Obese

7

-5.1

-

-15

n.s.

-

-

-40

-3

Obese & T2DM

7

-3.6

-

-105

n.s.

-

-

-110

-15

-

Obese

18

-5.3

-14

-

-34

-23

-7

n.s.

-15.3

-15.3

-5.6

-20

-

-47

-42

0.7

n.s.

-8.1

-19.9

Obese & T2DM

16

-2 (BMI)

-

-32

-

-

-

-

-2.3

-

VLCD

Obese & MetS

9

-2.3
(BMI)

-

-11

-

-

-

-

-2.5

-

RYGB-diet

Obese & T2DM

10

-7.3

-

-36

-

-

-

-

-

-

-4

-

-28

-

-

-

-

-

-

Water
VLCD

Obese & MetS

RYGB
Water

Overweight &
HTN

174

-6.3

-31.7

-

-

-

-

-

-

-

14

Water

Overweight &
pre-HTN

68

-7.7

-17

-

-

-

-

-

-

-

Umphonsat
hien 2019

14

VLCD

Obese & T2DM

19

-9.5

-

-108

n.s.

-

n.s.

-38

-6.1

-

Leiter 1984

14

VLCD

Obese

12

-7.8

-6

-

-

-

-

-

-

-

Morel 2011

30

VLCD

Obese

24

-6

-6

-11

-54

-70

-12

-12

-3

-25.2

Henry 1986

36

VLCD

Obese & T2DM

10

-11.1

-

-190

-45

-

-6

-58

-18

-

Obese

5

-16.2

-

-20

-121

-

-7

-295

-26

-

Marliss
1970

42

Water
(+NaCl/KCl)

Obese

14

-21.3

-

-15

-

-

-

-

-25

-

-14.5

-19

-68

-40

-38

n.s.

-46

-

-

60

VLCD

Obese & new
T2DM

15

Steven 2015

Obese &
chronic T2DM

14

-13.9

-27

-90

-42

-38

n.s.

-19

-

-

15

The data in Table 1 demonstrate that changes in the biomarkers of metabolic
illness are acute, largely independent of changes in body weight, and meet or exceed the
expectations for guideline-recommended chronic dietary interventions. Hypertension: a
mere 2 days of VLCD resulted in a drop in systolic blood pressure of 17 mmHg (reaching
below hypertension cutoffs)

49

. By comparison, a recent network meta-analysis of dietary

interventions for blood pressure found that the DASH diet results in between 2.3 to
8.7mmHg drop in systole

67

. Hyperglycemia: 3 days of VLCD resulted in a drop of fasting

glucose by an average of 100mg/dL (to a below-diabetic level in this group). By
comparison, a recent meta-analysis of low glycemic index diets for T2DM found a
standard mean reduction by ~2mg/dL

68

. Dyslipidemia: 7 days of VLCD in patients with

MetS resulted in a reduction of TC by 47 mg/dL, LDL by 42mg/dL

53

. By comparison, the

low glycemic index diet for T2DM resulted in a standard mean reduction of TC by
6.4mg/dL and in LDL by 8mg/dL

68

. Resistance: Insulin and leptin levels also both drop

substantially during the first few days of VLCD/fasting. Further, there was a reduction in
markers of insulin resistance (e.g. glucose tolerance test

69

and insulin clamp 66) and leptin

resistance (soluble leptin receptor levels (Lep-R) 53) after a week of VLCD/fasting.
The rapidity of these results in these small, highly controlled experiments is
equivalent or superior to the aggregated changes observed in large scale, randomized
control trials of dietary interventions run over several months. Interestingly, it appears
that as the length of the VLCD/fasting intervention increases, weight loss continues
linearly but the biomarkers begin to stabilize. The level of analysis offered in these studies
16

did not examine whether the leveling off occurred once pre-disease levels were reached;
however, VLCD and short-term fasting with supplementation are well-established to be
safe 70,71 (see section 1.2.4). This is unlike the drugs that forcibly reduce the blood levels
of these biomarkers; these medications, such as insulin for hyperglycemia or certain
alpha-receptor 2 agonists like clonidine for hypertension, can induce pathologically low
levels that harm human health 70,71.
Short term negative energy balance is also sufficient to reduce serum
concentration of hormones that are normally chronically elevated in MetS - insulin
76

and leptin

50,76–78

72–

among others. These findings are largely independent of substantial

fat-mass loss (see citations in Table 1 for more information - the methods for fat mass
determination are too heterogeneous to report in a systematized way). However, as
discussed above, excessive adiposity appears to be a prerequisite for the development of
leptin and insulin resistance and then metabesity.

1.2.3. The acute-on-chronic overeating model of metabesity
It seems that it is neither the case that people are "healthy at every size" nor that
possession of certain level of adiposity is sufficient to drive the expression of various
metabolic diseases. Instead, I believe it will be useful to introduce the concept of acuteon-chronic overeating (ACO) as the best descriptor of the etiology and driver of
metabesity.
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ACO is a concise summary of the following concept, introduced in Section 1.2.1.2.
Over a protracted period of time, overeating (i.e. eating beyond caloric need) results in
weight gain and eventually, adisopopathy Eventually, the adisopopathy is significant
enough that the excess energy cannot be stored inside adipocytes, and instead circulates
in blood. That is ACO, and it drives the elevation of biomarkers known to be causal in the
development of metabolic disease. Figure 2 depicts this concept graphically where, for
known quantity of calories in excess of total daily energy expenditure (TDEE) and
dependent upon the level of adiposity, excess energy is stored in white adipose tissue
(WAT), visceral adipose tissue (VAT), or ultimately manifests itself in the blood for a period
of time (such as hyperglycemia or dyslipidemia). The molecular evidence for these
dynamics has been established

47,48,79–81

. Each point represents a different day for a given

individual across several years.
A)

At point A, the patient has relatively low adiposity and is consuming only as many
calories as is needed to meet their TDEE.

B)

Either because of increased energy consumption or the same amount of energy
consumed as in point A but with reduced TDEE, the patient now consumes excess
energy; it all gets stored into WAT.

C)

Between point B and C, the patient continued to eat above the TDEE and gained
significant adiposity. This results in leptin and insulin resistance and cellular
mechanisms preventing further incorporation into adipocytes

82

. Thus, some of the

18

excess energy is incorporated into VAT or deposited into extracellular locations.
Notably, it is hypothesized that the failure for WAT and VAT tissue to undergo further
adipogenesis to accept the excess energy may instead cause the release cytokines
driving the chronic inflammation phenotype so commonly seen in MetS 81,83,84.
D)

Between point C and D, the patient gains even more weight, despite consuming
less energy. It is still above TDEE and neither the WAT nor VAT can functionally accept
any further energy; this instead is spilled into tissue-deposited extracellular fat (such
as seen in non-alcoholic fatty liver disease), or into the blood as hyperglycemia,
dyslipidemia, etc.

E)

An acute reduction in caloric intake below TDEE, such as seen in Table 1, means no
further excess energy is spilled into the blood; after several days allows dissipation of
some resistance mechanisms, biomarkers of metabesity reduce substantially.

F)

Over

time,

patients

unconsciously

increase

calorie

consumption

despite

supposedly maintaining a diet (see section 1.3), and arrive at a heaver weight with
intake matching TDEE.
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Figure 2. A schematic of how metabesity is derived from acute-on-chronic
overeating
A schematic demonstrating the development of metabesity by continuous and chronic
overeating. Across a given patient's life time (points A-F), as they consume energy above TDEE,
they (B) first incorporate the excess energy into WAT (C), then VAT (D), then dump the remainder
into the blood as biomarkers of metabesity, causing further disease (e). Dramatic reduction in
energy intake results in no further excess energy being spilled into the blood and reduced risk,
without requiring sustained weight loss (F). TDEE= total daily energy expenditure; WAT = white
adipose tissue; VAT = visceral adipose tissue. See section 1.2.3 for citations and further details.
NOTE: this is not meant to be predictive of all aspects of metabesity, but instead to
demonstrate that, in true negative energy balance (which in some people may require eating
only VLCD), these biomarkers remit quickly.
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NOTE: Hypertension (HTN) deserves some special discussion, as it is less directly
related to overeating compared to the other biomarkers of MetS and metabesity

85

. First,

excess energy intake causes hyperinsulinemia with increased sodium-water retention this causes acutely readily-reversible HTN

86

. Second, obesity-linked leptin resistance

appears to drive elevated sympathetic activity, resulting in increased renal response with
release of renin - this is reversible across several days to weeks as described above.
However, physical compression of the kidneys by fat and damage secondary to both HTN
and glomerular hyperfiltration lead to early and permanent kidney damage. Since chronic
kidney disease itself causes HTN, but HTN is an etiological factor in so many other chronic
diseases, it can be considered both a biomarker and a sequela of metabesity.

1.2.3.1.

Interpreting the ACO model and its caveats

There is extensive evidence that chronic exposure to hyperglycemia, dyslipidemia,
hypertension, and chronic inflammation are the etiological agents that cause end organ
damage

37,70,87

. Understanding the origin and preventing chronic exposure is the major

challenge of medicine today. The ACO model presented in Figure 2 provides a unique
explanation of the origin and persistence of these biomarkers while incorporating a wide
body of evidence. First, it provides some validity for the "Health at Every Size" public
health approach, wherein meaningful reductions in exposure to risk factors for serious
disease can be accomplished just by short-term reduction in feeding behavior. For
example, a recent randomized control trial of a 7 day VLCD for patients with T2DM
provides some evidence for this; it found that 4 months after the VLCD ended, the fasting
21

group sustained reduced BMI, SBP, serum glucose, and had an increased subjective
quality of life

88

. Second, it incorporates the concepts of metabolically healthy obesity,

unhealthy obesity, and adiposopathy. As adiposity increases, the same amount of excess
energy consumption is spilled into VAT, then the blood, rather than inducing
adipogenesis/ hypertrophy and incorporation into newer/bigger cells. Third, it anchors
eating behavior as a fundamental determiner of metabesity as a whole, both in it's
etiology and continual manifestation.
Of course, much of the difficulty in studying the origins of metabesity arises from
how many knobs can be tuned to move a threshold seen in Figure 2. For example, when
three individuals are exposed to the same food environment, the fact that one remains
healthy throughout life, one develops type 2 diabetes mellitus, and one develops
hypercholesterolemia is a manifestation of genetic susceptibility. Indeed, there are
hundreds of metabolic knobs that can be tuned to alter basal metabolic rate and energy
expenditure. For example, some individuals with hypothyroidism have reduction in basal
metabolic rate (and hence reduced TDEE) and consequently gain substantial amounts of
weight in relatively short periods of time, despite eating the same or fewer calories
Further, it is well-evidenced that metabolic factors such as excess cellular aging

92–94

89–91

.

and

sarcopenia 95–97 directly dysregulate normal levels of biomarkers of metabesity.
Exercise induces similar effects as short-term fasting on most metabolic factors
within a short period of time - likely representing increased TDEE. For example, 7 days of
high intensity interval workout

98

produced similar improvements in insulin resistance in
22

individuals with metabolic illness. Mechanisms driving this are currently under research,
such as how mitochondrial exposure to excess fatty acids leads to incomplete fatty acid
oxidation, contributing to skeletal muscle insulin resistance

83,99

and are reviewed in detail

here 74.
Dietary composition is also a major factor driving metabolic response to foods.
Macronutrient and micronutrient composition and the cellular and hormonal responses
to their ingestion substantially affect whether excess energy is stored into muscle, WAT,
VAT, or not incorporated. For example, high carbohydrate foods produce a higher peak
glucose concentration in the serum, provoke more insulin release, and cause more
storage of calories into fat or hyperglycemia in T2DM-susceptible individuals

100

.

Comparatively, extremely low carbohydrate diets (ketogenic diets) seem to produce
relatively less weight gain, are less likely to alter adaptive thermogenesis, and mimic
fasting's effects on circulating hormones for the same amount for calories

101–104

. Even

time-restricted eating, where the same amount of calories are consumed on a daily basis,
but only during a few hours per day, seems to reduce the amount of energy incorporated
into fat and hence is less "obesogenic"

105,106

. Heavy alcohol consumption is also a unique

driver of metabolic illness beyond the pure calorie content that is probably underassessed in the general population

107–110

. And of course, certain diets, particularly the

"Standard American Diet" (SAD) seem to induce over-consumption 75,111–113.
Nevertheless, ACO is an important and necessary etiological driver of not
only obesity, but most metabolic illness. It seems to be the primary common causal
23

factor; targeting overeating should be the first and most successful tool used by clinicians
for weight loss. Yet, it is rare for real-world medical practitioners to see their patients
successfully alter their lifestyle, at least in the United States. A synthesis of NHANES data
from 2011-2016 found that 55% of patients with T2DM report receiving any lifestyle
advice from their doctor; only 45% of obese patients, 30% of patients with high blood
pressure, and 27% with high cholesterol reported receiving lifestyle advice 114.
Why is this the case? This question will be explored in section 1.3 where standard
practice has not succeeded in resulting in sustained weight loss. However, it is first
necessary to discuss several concerns about the deleterious nature of weight loss, calorie
reduction, and fasting.

1.2.4. Commentary on the safety and efficacy of prolonged fasting and
calorie restriction when treating metabesity
It is worth noting that, to this day, the shadow of the Minnesota Starvation
Experiment (MSE) has an outsized negative influence on popular conceptions of fasting
and calorie restriction. An article published by Kelsey Miller July 11, 2016 on
news.yahoo.com is titled "The Starvation Study That Changed The World" and cites the
~1600 calorie amounts the men consumed (see below) and their subsequent
deterioration as incontrovertible proof that even mild reductions in calorie intake are
dangerous and harmful, which is typically extended to view fasting as very dangerous.
Indeed, studies that recapitulate the MSE in recent decades further use this to support
both the conclusion that even 50% calorie restriction leads to rapid starvation, post-
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dieting binging behavior, and irreversible compensatory adaptive thermogenesis

115

. This

is commonly invoked to explain the extremely high relapse of contestants in the television
show Biggest Loser, where a followup study found that they reported eating fewer calories
per day but that their estimated metabolic rate was reduced, causing them to regain all
of the weight they lost

116

. As discussed below and in the longer-term fasting studies in

Table 1, however, more rigorous analyses do not actually support these conclusions and
often show the opposite. Why is there such discrepancy? It may be due to a
misinterpretation of the MSE itself. Since these ideas owe their conceptual origin to the
MSE and are extraordinarily common in the clinical world as a counter to
recommendations of food restriction, it is worth discussing the MSE in some detail.

1.2.4.1.

The Minnesota Starvation Experiment

The MSE was conducted by Josef Brozek and Ancel Keys, developed initially to
simulate wartime starvation in Western Europe

. Early observations were published in
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1948 and later incorporated into a book titled The Biology of Human Starvation (1950,
University of Minnesota Press). In this study, 36 young adult men were fed on a diet of
~3500 calories for 3 months, then on ~1600 calories for 6 months, then refed with slowly
incremented increased in calories/macronutrient content for another 3 months, then
finally given unrestricted food access for a final 2 months. Perhaps surprisingly given the
data in Table 1, by 3 months the subjects had all of the symptoms of starvation such as
muscle wasting, edema, micronutrient deficiency manifestations like paresthesia, slow
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wound healing, hypokeratosis, etc. After the rehabilitation period, they consumed heroic
amounts of food. It is illustrative to quote this section of the article directly:
[...] on the weekend of October 20, the whole group was at long last free to
satisfy their personal food cravings and, most importantly, to eat as much as they
wanted. The men gorged prodigious quantities of food, which approximated six to
seven thousand calories per day. Many ate more or less continuously throughout
the two-day period. Some reported eating as many as three consecutive lunches.
[...] The free choice of ingredients, moreover, stimulated “creative” and
“experimental” messing with food. Licking of plates and neglect of table manners
persisted. Attempts to avoid wasting even a particle continued in the face of
unlimited supplies of immediately available food. An irrational fear that food
would not be available or that the opportunity to eat would somehow be taken
away from them was present in some of the men. This may have motivated their
eating as much as they could hold at any given time [...] Follow-up studies made at
thirty-three and fifty-five weeks after the end of semi-starvation showed that the
men had returned, by and large, to their pre-experimental “normal” status except
that a number of men exceeded their pre-starvation weight.
The technical aspects of the Minnesota Starvation Experiment clearly showed
these men had indeed undergone starvation. Dr. Key's work on the techniques of safe refeeding and avoiding re-feeding syndrome provided critical evidence that has saved
thousands upon thousands of lives. However, he was not a psychologist; further, there is
some controversy surrounding the selection of data used to demonstrate an association
of increased dietary fat with cardiovascular disease mortality across countries

118–120

. There

are several major confounders that limit the applicability of the MSE to all forms of calorie
restriction:
1.

The subjects were volunteers, but were selected from a pool of draftees who were
conscientious objectors, usually for strong religious beliefs such as being a Quaker,
and in later interviews they discuss their desire to be doing "something" for the war
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effort, since they could not deploy. Thus, some of the intensity of emotions reported
may be a reflection of the personality type. Further adding to the behavioral
consideration, they were kept isolated for an entire year and asked questions
incessantly about hunger.
2.

Their diet was extremely high carbohydrate - meant to reflect wartime food
supplies in Europe, according to a recent estimate, it only provided 55g/d of protein
115

. While debate is ongoing, evidence has emerged that meeting a minimum

threshold of protein consumption per day is much more important than calories for
preserving muscle mass and maintaining growth hormone during calorie restriction
121,122

. Hence, some of the starvation was exacerbated by specific nutrient deficiencies

rather than caloric restriction.
3.

The subjects were also required to exercise and walked 20+ miles per week and
had non-specified "work" to do around the camp. Thus, energy expenditure was much
higher than would be expected for the average 21st century American adult.

1.2.4.2.
Extended therapeutic fasts show high tolerability, minimal
reduction in basal metabolic rate beyond expected for weight
These factors likely reduce the relevance of the MSE to understanding therapeutic
fasting and calorie restriction to the average healthy or metabese individual, though
certainly do not affect the importance of this study for understanding starvation. As
alluded to in Table 1, numerous prolonged fasting studies (>1 month without calorie
consumption) for treatment of obesity, conducted in the wake of the MSE, did not
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replicate these findings

123–127

. In discussion section of Drenick et al. 1964, for example, the

authors make the following observations on 11 patients with metabesity treated by
prolonged fasting and a supplement containing 5000U vitamin A, 400U vitamin D, 2mg of
thiamine, 3mg of riboflavin, 75mg of ascorbic acid, and 20mg of nicotinamide 123:
The most astonishing aspect of this study, to the patient and to the
physician, was the ease with which prolonged starvation was tolerated. This
experience contrasted most dramatically with the hunger and suffering described
by individuals who, over a prolonged period, consume a calorically inadequate
diet. It is remarkable that the fast seemed easier for the patient the longer it lasted.
[...] most subjects will be able to continue long enough to reach the point when
appetite or hunger is no longer felt. From then on, he fast can be safely continued,
provided close clinical supervision is maintained. It is not clear why the sensation of
hunger subsides, but the disappearance is apparently not related to ketosis. It is
also interesting that severe, prolonged hypoglycemia does not produce the hunger
sensation or other symptoms associated with abnormally low blood-sugar levels.
[...] Those who attained an normal body weight were enthusiastic and delighted to
resume living as normal-weight human beings. The eating habits and appetites of
these individuals seemed to have undergone a decisive change; and, during a
limited follow-up period, these patients seemed to have little difficulty in
maintaining their weight.
The fact that every descriptor here runs counters to those seen in the MSE
indicates, again, that it may not be representative of all persons experiences with fasting.
There are certainly complications associated with long-term fasting and the attendant
rapid weight loss such as choledocholithiasis

128

or the possibility of electrolyte depletion

in a small subset of susceptible individuals especially during the early natriuresis phase
86,129

. The question as to whether binging behavior occurs after dieting, compared to

being an unacknowledged cause of the original weight gain, is not so easy to answer. The
inherent act of dieting will make subjects more attentive to their eating behavior and
hence a positive confirmation bias if they feel they are struggling with maintaining the
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diet in general.130,131 On the whole, subsequent research errs far more on the side of
Drenick than Keys when it comes to understanding the effects of voluntary, proteinsparing and micro-nutrient-repleted fasting 65,105,132.

1.2.4.3.

Metabolic fasting versus "overnight fasting" in medical research

Before moving on to discussing modern day successes and failures with dietary,
medical, and bariatric interventions for metabesity, two questions related to this data
remain:
1) If fasting reverse metabesity biomarkers, why has so much importance been placed on
"fasting glucose" and "fasting cholesterol" as markers of metabesity?
The answer is that in the medical literature, "fasting" almost uniformly refers to
"morning before breakfast" samples. The questionable utility of this metric can inferred
from the results of an elegant study by Shubhroz Gill and Satchidananda Panda

. In this

106

study, they deployed a cellphone app to 47 subjects; the subjects took pictures of
everything they ate that were then calculated for caloric content by the experimenters.
They also sent several push notifications per day asking if the subject had eaten anything.
This was combined with an activity tracker (wrist actigraphy) that allowed assessment of
baseline eating habits compared to wake-sleep times over 3 weeks.
The results of this study were striking and best put in Dr. Panda's own words: "if
your eyes are open, your mouth is open". Subjects ate food within the first hour and a half
of waking up (median 1hr 18 mins) and two and a half hours before bed (median 2hrs 22
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mins). Amount of time slept per night varied widely, but generally was between 6-8 hours.
Further, the data revealed the subjects did not really consume 3 meals per day, but
instead distributed calories fairly evenly across the day.
While not the focus of Gill and Panda's study, it reveals that a "morning fasting
glucose level" or "overnight fasting cholesterol level" probably represents between 8-14
hours after the last eating event. From the perspective of whole body metabolism, this is
not very much time and sits in the middle of a transition period between the metabolic
postprandial period and true fasted state. While a detailed review of the transition from
fed to fasted state is beyond the scope of this dissertation (see here for such an overview
133,134

) it is clear that a “true” fasting physiology, predicated upon the cessation of glycolysis

and initiation of ketosis, does not fully engage until at least 24 hours after the last eating
event. Figure 3 shows the dynamics of glucose, ketones, leptin, insulin, total cholesterol,
and triglycerides during the transition from the early post-prandial period (4hrs after last
meal) to the fully fasted, ketosis state (48hrs after last meal), derived from data reported
here 135 and reviewed more extensively here 63,127,136. The massive variations in these
biomarkers seen between ‘fed’ and ‘fasting’ days seen in alternate-day fasting studies
demonstrates the importance of this nuance 135.
Notably, the literature often refers to the 48-72hr period when ketone bodies
become the primary source of fuel as "starvation". It is important to differentiate this
from the medical conditions of starvation; these are the diseases of chronic malnutrition,
either from total energy restriction or insufficient intake of proteins or lipids with
30

isocaloric intake (predominated instead by carbohydrates)

136

. Manifestation of these

diseases include loss of subcutaneous fat (e.g. 'sunken eyes'), muscle loss in a useindependent manner (e.g. wasting of the temples and reduced grip strength), and pitting
edema due to reduced activity of ATP-dependent ion pumps

136,137

. It appears that the

negative consequences of protracted fasting/starvation are due to depletion of nitrogen
(technically, loss of electrolytes may be the first negative effect). The timeline for the
onset of significant nitrogen-loss induced muscle wasting is likely weeks after the
beginning of fasting

138

and is due primarily to the need to balance urinary excretion of

anion ketone bodies with ammonium

139

. Providing exogenous sodium bicarbonate and

potassium chloride is sufficient to substantially reduce ammonium excretion and preserve
muscle mass 140.
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Figure 3. Serum metabolite changes during the fed-fasted transition
The data presented are derived from Browning et al 2012
extensively in the literature

134

and concepts elaborated

. The bottom of each graph segment represents

63,125,133,134,138,141–144

the lowest recorded average value in that condition and the top represents the highest
recorded average value: glucose, 73-90 mg/dL; ketones, 0.05-1.94 mmol/L; insulin 3-16 µU/mL;
leptin 1.8-19.3 ng/mL; triglycerides 75-115 mg/dL; total cholesterol 145-176 mg/d. The percent
change from 4hrs to 24hrs compared to 48hrs was used to determine the location of the 24hr
inflection point; a sigmoid line was used based off of aforementioned references. For glucose,
%Exog means percent derived from exogenous sources, %Glyc means % derived from
glucagon, and %Glcng means % derived from gluconeogenesis
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Compared to the detrimental effects of starvation, glycogen depletion and reliance
on ketone bodies is not inherently physically impairing. It has long been reported that
long-distance runners and hikers can enter into ketosis after several hours of physical
exertion

145

tolerance

, that non-energy-restricted ketogenic diets do not meaningfully alter exercise
102,103

, and that calorie-restricted ketogenic diets may actually improve

endurance exercise performance 146.
My conclusions from this data are twofold. First, "overnight fasting" does not
represent a true "fasted" value that might reflect the baseline metabolic dysregulation
stemming from sarcopenia, excess adiposity, genetic variation, etc. Second, there is a
significant difference in the metabolic effects of fasting and ketosis versus starvation. The
first two are much safer than may initially be believed; however, this leads to the second
question.
2) In healthy individuals, fasting decreases insulin sensitivity: isn't it paradoxical that it would
improve insulin sensitivity in T2DM and metabesity generally?
This delves into the topic of tissue-specific insulin resistance and sensitivity and the
progressive sparing of glucose for tissues that require glucose to function - namely the
brain (potentially only glia), red blood cells, and the renal medulla

63

. In a healthy

individual, we would expect that, as glycogen stores are depleted and ketone bodies are
produced alongside liver gluconeogenesis of glucose, it is adaptive to prevent the liver
and muscle from utilizing the gluconeogenesis-originated glucose since they can use
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alternate fuels (see Figure 3) 134,148. Thus, those tissues develop insulin resistance.
However notably, this only occurs in relatively low levels of serum glucose. In individuals
with metabesity, excess serum glucose has induced insulin resistance in liver, muscle, and
adipose tissue with concomitant high levels of leptin and leptin resistance. Once the
adipocytes begin liberating free fatty acids for conversion into ketones in the liver, they
regain relative insulin sensitivity as they are no longer at what can be referred to as
storage capacity

74,141,147–149

. Similar statements can be made about total cholesterol. While

fasting induces an increase in serum cholesterol and free fatty acids in order to supply
ketone bodies in healthy individuals, this increase is likely much smaller in magnitude as
is seen in hypercholesterolemia – instead, hypercholesterolemic individuals see a relative
reduction in serum cholesterol over time, because more is being utilized 149.

1.3.

Medical treatment of overeating is ineffective.
The best evidence indicates that dietary and exercise interventions only delay the

onset of metabesity for a few years, though this still is a highly cost-effective way to
reduce morbidity and mortality
providing such advice

. Most physicians report not seeing much utility in

150,151

. Further, there is a major gap in the patient education

152–154

guidelines currently available for treatment of obesity, and the difficulty of implementing,
in practice, lifestyle modification

155,156

. For example, few studies even report physician

adherence to psychotherapeutic interventions like motivational interviewing across time
.

157
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1.3.1. Dietary changes and lifestyle intervention fail primarily because of lack
of adherence
Most studies that evaluate weight loss find a plateau effect around 6 months. This
has traditionally been attributed to reductions in resting energy expenditure (ERE) that
are disproportionate for an individual’s body weight

116,158–162

. However, accounting for

differences in ERE does not appear to predict the amount of weight regained 16 163 It may
even reflect a discrepancy in the way ERE is measured. There is wide variability in
estimations of TDEE and fat-free mass-adjusted ERE (which determines true metabolic
need). Further, in more tightly controlled studies, such as in a month-long alternate day
fasting regimen

135

, or a 6 day metabolic ward trial

52

, no reduction in TDEE was detected.

Interestingly enough, it appears that these findings are strongest in studies of long-term
weight loss with reduced monitoring of patient activity, and generally a recommendation
for "continuous energy restriction" (i.e. cutting calories) either in proteins or in fats

164

.

Fasting generally preserves TDEE. It seems to be the case that diets promoting growth
hormone expression (fasting, low carbohydrate) are least likely to have this effect. Thus
there is a possibility that the reduction in TDEE may be appropriate for the amount of
weight lost or attributed to one specific dietary intervention 165–169.
The lack of patient monitoring is important, because it is also clear that dietary
adherence is often not sustained for lengthy periods of time. Relapses in behavioral
interventions often begin to occur 6 months after a change in habit, which times quite
closely with the weight loss plateau observed above 163.
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This occurs even after highly controlled intensive lifestyle therapy and training, as
was tested by the Look AHEAD Research group comparing this intervention to
conventional diabetes support and education in over 5000 patients

170

. As soon as the

intensity of intervention ended one year after the trial began (with substantial
improvements compared to conventional treatment), weight began to increase again
and glycemic control diminish. The study's methodology makes it clear this was primarily
due to failure to continue adherence to the intervention - ultimately, 10 years after the
study was started, there was no significant difference in rates of cardiovascular morbidity
and mortality. The failure of this intensive behavioral intervention to produce weight loss
has been replicated in many other studies

171

. Given that weight loss per se is not

necessarily the only factor that is going to cause dietary intervention to reduce morbidity
and mortality from metabesity (Figure 2), these findings could indicate that the patients
may no longer successfully diet at any meaningful rate. A recent review of literature on
lifestyle modification for weight management has shown that factors such as depression,
stress, unemployment, strong body shape concern, and a history of previous failed
weight loss attempts all predict poor adherence to change 172.

1.3.1.1.
Evidence from medication adherence that long-term behavioral
change is a serious barrier to treatment
However, it is not necessarily easy to determine what a person's real dietary habits
are. The Gill & Panda 2015 study using cellphone push notifications, discussed in section
1.2.4.3 provided valuable insight into 'standard' human eating behavior, which does not
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really reflect the perceived cultural norms of eating 3 meals a day, for example

106

.

However, even the app still relies on accurate patient reporting.
Adherence to medication regiments has been more extensively studied examining this field may provide insight into dietary adherence. Certainly, there are
differences in motivation for a patient to adhere to lifestyle intervention compared to a
medication, since weight loss and fitness are positively reinforcing whereas medication
side effects are almost uniformly negatively reinforcing. However, medication regimens
are far simpler to follow compared to a lifestyle intervention and require less
intentionality throughout the day - intuitively, it would appear that adhering to
medications is logistically simpler than to a lifestyle intervention.
Unfortunately, it appears medication adherence rates are generally poor and get
worse the more rigorously patient behavior is examined or the more complex the
regimen becomes. A retrospective analysis of 5,500 hypertensive medication refills over
one year at two community pharmacies in Washington state found that, in total, ~75% of
all prescriptions were filled in compliance with the regimen

173

; however, when narrowed

down to the first three months after initiating a prescription, 35% of patients were
undercompliant (did not refill enough times). Complexity of regimen, such as taking
several medications at once, reduces adherence, as does the type of drug (lipid lowering
drugs have a nearly 20% drop in adherence compared to anti-hypertensives) 174.
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1.3.1.2.
More intensive observation of medication adherence reveals
challenges with delivering effective, patient-controlled therapy
This does not address the question as to whether the patients are actually taking
all of the medication received at each refill or following instructions to take the medicine
in an efficacious way (for example, thyroid hormone should not be taken with food as it
has dramatically reduced absorption). To answer this question, objective biomarkers of
drug presence or efficacy can be analyzed.
Biomarkers: A recent analysis on the subject of medication adherence notes that the
Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial for HIV per-exposure
prophylaxis (Pr-P) was a surprising failure to differentiate, despite enrolling over 5000
patients

175

. In this study, 90% of patients reported taking the medication 100% of the

time and pill counts suggested 86% of doses were taken: however, only 30% of blood and
cervicovaginal fluid samples had detectable drug. The drugs themselves were wellestablished and effective clinically, indicating it was not a formulation issue.
Drug efficacy: Curing tuberculosis requires a 4-medication regimen for many months; to
increase cure rate and reduce the hazard to the public health, governments have
implemented directly observed therapy (DOT) across the world. In most cases, the
medication is free to the patient whether self-administered or through DOT; thus, a
comparison of cure rates in a given time period can elucidate the degree of influence that
habitual non-adherence (rather than economic factors) has on real-world drug efficacy. A
2015 Cochrane Review of six trials from Africa, Thailand, Taiwan, Pakistan, and Australia
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interestingly showed that DOT was not more effective than self-administration (RR 1.08) in
resulting in cure (between 41-67% of the time)

176

. However, this was actually modified by

the control condition where patients still went and picked up medication very frequently;
if the patient only refilled their prescription once per month, DOT was more effective (RR
1.15). Thus, frequent contact with healthcare providers provided an external reinforcer for
adhering to medication to a great enough degree to result in a cure. This is in keeping
with the the Look AHEAD study's result, where the beneficial effect of intervention was
maintained so long as there was the frequent contact with a provider.

1.3.2. Bariatric surgery - forcible adherence to dietary intervention
Given that patients struggle with adhering to behavioral changes long term
without extensive, frequent support,

medicine has long sought tools to increase

assistance; namely, bariatric surgery and anoretic agents. Bariatric surgery is an
aggressively simple solution to the problem of low adherence rates - shrink the stomach
so overeating is extremely uncomfortable, or remove enough intestine so excess calories
cannot be absorbed. The first well-documented bariatric surgeries for weight loss
occurred in the 1950s in Germany, with major resection of the small bowel

177

. This

extremely effective, but those patients suffered from severe malnutrition and no way to
reverse the operation.
In response to this, bariatric surgeons have rerouted and restricted the stomach
and intestines in a wide variety of ways. These less drastic surgeries, such as the
laparoscopic gastric banding (LAGB) produces fairly unimpressive results in the prolonged
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remission of metabesity and require frequent revisions because of band slippage

178

. The

surgeries with substantial intestinal rerouting like the Roux-en-Y gastric bypass (RYGB)
appear to sustain weight loss and remission of metabolic illness; for example, in a
randomized control trial comparing RYGB to LAGB in T2DM, the mean reduction in
percent body weight was 25% and 15% respectively

178,179

. If we assume these patients

were at the minimum BMI with T2DM to be included (35), that means the RYGB resulted
in an average reduction of 9 points (to 26) whereas the LAGB reduced by 5 points (to 30).
The RYGB has also been shown to substantially reduce blood pressure and other
cardiometabolic risk factors - likely, the number of indications for RYGB will increase in
the future 180.
Bariatric surgery may be a necessary intervention in some subset of people and
appears to successfully induce sustained remission in certain cases. It has the benefit of,
in the most invasive types, having very high long-term success rate, at least in the field of
remission of metabesity. However, it is expensive, time and labor intensive, and requires
close outpatient follow-up with substantial vitamin and mineral supplementation, and has
an estimated 4.4% readmission rate within 30 days of the operation
surgeries, moreover, usually require at least one surgical revision

181

178

. The less-invasive

. All of this means

bariatric surgery will likely not become a primary go-to approach to treating metabesity.

1.3.3. Pharmacotherapy for weight loss has limited efficacy
Because drugs are far easier to reliably administer and adhere to as
compared to lifestyle interventions, and generally much safer and more reversible than
40

bariatric surgery, there has been a long history of pharmacotherapy targeted towards
weight loss. Perhaps not surprisingly, given the data in Figure 1, none of the available
drugs are all that efficacious; otherwise, most Americans would be on them.
I

have

consolidated

the

most

clinically

well-established

and/or

unique

pharmacotherapy for weight loss and reversal of metabolic illness into Table 2. Each drug
listed has either previously been marketed in the U.S. or Europe for weight loss and since
removed (strike-through), is currently FDA approved for weight loss (highlight), has been
used off-label to assist with weight loss, has been used in off-label clinical trials, or is
currently undergoing research. Phase is indicated with year of last known result published
either in an academic paper or on cinicaltrials.gov. Date of FDA approval, if not widely
known, was taken from accessdata.fda.gov.
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Table 2. Pharmacotherapy for weight-loss
Consolidated from multiple sources 23,182–223. Highlighted and bold drug names currently
have FDA approval for weight loss. Italicized and underlined drug names are only
investigational; for these, I have only listed the most successful (has reached Phase 1 clinical
trials or has been studied in humans). Strike-through drug names were used clinically but have
since been removed from the market. Dates indicate FDA or European approval for any use, not
just weight loss; if not approved, latest research status indicated. * indicates commercially
available without prescription.
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Monoamine Release
Dopamine reuptake inhibitor

Methylphenidate 1955
Bupropion 1985
Fenbutrazate 1957

Norepinephrine-dopamine
reuptake inhibitor

Modafinil 1998
Phenylpropanolamine 1947
Pipradol 1953
Diethylpropion 1950

Norepinephrine releasing agent

Phendimetrazine 1960
Phenmetrazine 1954

Monoamine Receptor
5-HT1A agonist / 5HT2A antagonist

Flibaserin 2015

5-HT2C agonist

Lorcaserin 2012

5-HT receptor family agonist
Beta-3 agonist

Mirabegron 2012

D2R agonist

Bromocriptine 1975

D3R antagonist

Gsk598809 Phase I (2010)

H1R agonist, H3R antagonist

Amylin analog

Pramlintide 2005

Sibutramine 1997

Diazoxide 1973

LMWCr-binding substance agonist
(insulin receptor PAM)

Amphetamine 1935

CCK1R agonist

Benzphetamine 1960

FGF21 analogue

Dextroamphetamine 1996
Fenproporex 1966
Levamphetamine 1944
Mazindol 1973
Mefenorex 1966
Methamphetamine 1944
Phentermine 1959

Pegbelfermin Phase II (ongoing)

FGF4 receptor antagonist

Tesamorelin 2010

PDE4 inhibitor

Roflumilast 2010
Sildenafil 1998

PDE5 inhibitor

Tadalafil 2003
Recombinant HGH 1985

Somatostatin mimetic

Octreotide 1998

TBK:IκB kinase inhibitor (reduces
downstream NF-κB activation)

Sheep’s thyroid extract 1890s
Thyroid hormone mimetics and
metabolites

Eprotirome Phase II (2008)

Fenfluramine 1973

Sobetirome Phase II (2018)

Sertraline 1991

Neuropeptide/Neurohormonal Modulation

Cellular Metabolism
Pleotropic inhibitor of ER stress (insulin
sensitization)
Increases intracellular nad/nadh ratio

AgRP inhibitor

TTP435 Phase II (2009)

Dual GLP1-GCGR agonist

Cotadutide Phase I (ongoing)

Intestinal diacylglycerol acyltransferase
1 inhibitor

Dual GLP1-GIPR agonist

Tirzepatide Phase III (ongoing)

Matrix metalloproteinase inhibitor

Efpeglenatide Phase III (ongoing)
Exenatide 2005
Liraglutide 2014
Semaglutide Phase I (ongoing)

MC4R agonist
MCH1R inhibitor
Mu opioid receptor competitive
antagonist
Y2R agonist

Metreleptin 2014

Bms-830216 Phase II (2015)
Naltrexone 1984
Naloxone 1971
PYY3-36 Phase II (2008)
Obinepitide Phase II (2007)

Y5R antagonist

Velneperit Phase II (2011)
Oxytocin Phase II (ongoing)

Microsomal triglyceride transfer protein
inhibitor

Metformin 1957 (EU) 1995 (US)
Phenformin 1958
Pf-04620110 Phase I (2011)
Als-l1023 Phase III (2015)

Oxidative phosphorylation decoupler

Beloranib Phase III (205)
Lomitapide 2012
2,4-dinitrophenol 1930s

Sirt1 allosteric activator

RZL-012 Phase II (ongoing)
Phase I-III (ongoing,
many)

Resveratrol

Nutrient re/uptake
Intestinal glycoside hydrolase (alphaglucosidase) inhibitor

Acarbose 1995

Exocrine (Pancreatic/ Intestinal) lipase
inhibitor

Orlistat 1999

Miglitol 1996
Cetilistat Phase III (ongoing)
Dapagliflozin 2014

Sglt2 inhibitor

Canagliflozin 2013

Combination therapy
Fenfluramine/phentermine

1992 (never official)

Rimonabant 2006

Bupropion-naltrexone

2014

Taranabant Phase IIII (2008)

Dapagliflozin-exenatide

Phase III (ongoing)

Phentermine-topiramate

2012

Pramlintide-metreleptin

Phase II (2009)

Topiramate 1996
Pleotropic ion channel modulator

Sodium phenylbutyrate 1996

White→Brown adipocyte differentiator

Neurotransmitter Release
Cb1 inverse agonist

Tauroursodeoxycholic acid Preclinical (ongoing)*

Methionine aminopeptidase 2 inhibitor

Setmelanotide Phase III (ongoing)

Y2R/Y4R agonist
OxyR agonist

3,5-diiodothyropropionic acid Phase II (2007)

Dexfenfluramine 1995

Fluoxetine 1986

Leptin receptor agonist

Amlexanox 1996

Iodinated casein strophanthin 1944

Benfluorex 1973

GLP1 agonist

ISIS-FGFR4RX Phase II (2016)

GHRH analogue

Tesofensine Phase III (ongoing)
Clortermine 1973

Chromium picolinate 1989*
GSKI181771X Phase II (2009)

Chlorphentermine 1962

Serotonin reuptake inhibitor

Nicotine 1980s (gum)*

Endocrine/Immune
ATP-sensing K channel PAM (reduces
insulin release)

Clobenzorex 1966

Serotonin releasing agent

Ly377604 Phase II (2010)

Duloxetine 2004

Aminorex 1962

Serotonin-norepinephrinedopamine reuptake inhibitor

Betahistine 1972

Nicotinic receptor agonist

Phenylpropanolamine 1938
Serotonin-norepinephrine
reuptake inhibitor

Meta-chlorophenylpiperazine Preclinical (1970s+)

Zonisamide 2000

Combination of other medications
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1.3.3.1.

Five FDA-approved drugs that result in ~5-10kg weight loss.

Despite the extraordinary number of drugs that have been developed for weight
loss, only 5 drugs currently have FDA approval for long-term weight loss. They are
liraglutide, lorcaserin, bupropion/naltrexone, phentermine/topiramate, and orlistat. While
metformin is not FDA-approved for uncomplicated weight loss, it receives an honorable
mention in this list as it is commonly used as adjunctive therapy for antipsychotic-induced
weight gain and off-label for weight loss

215,224

. Diethylpropion, phendimetrazine, and

phentermine are only approved for assisting weight loss for the first few weeks. Note: at
the time of this dissertation’s submission to the graduate school, the FDA had requested a
voluntary recall for Belviq, the branded version of lorcaserin, because of a 0.6% increase
in cancer incidence (7.1% placebo (n=324) to 7.7% lorcaserin (n=462)) in a 12,000 person
randomized controlled trial. Whether this is a permanent recall is not yet known.
The first four FDA drugs all act on satiety signaling and the latter two reduce
energy uptake/utilization. They do not work well: the average weight lost on these drugs
over 8-12wks is between 6-10kg

. For a 170cm male, this represents a reduction by 1-2

204

points of BMI. With reference to Table 1, a similar amount of weight loss can be achieved
in 1-2 weeks via a VLCD or water fast. This is not surprising. The history and present state
of the search for weight loss medication is replete with examples of drugs that were
minimally effective and unpleasant such as the over-the-counter non-absorbable fat
substitute Olestra 225; mildly effective but addicting (such as amphetamines)

; and mildly

186

effective but with serious side effects. Such side effects include cardiac valve fibrosis
44

associated with serotonin-releasing agents,cardiovascular disease associated with
norepinephrine releasing agents like sibutramine, and depression and suicidality
associated rimonabant

191,196,226

. To my knowledge, no medication that has historically

been used for weight loss/reversal of metabolic illness via weight loss has ever surpassed
the 6-10kg mark in long-term efficacy. This is despite almost every imaginable molecular
target having been tested preclinically and often in clinical trials. At the time of this
writing, there continues to be breathless coverage of the many drugs currently
undergoing clinical trials for potential FDA approval for either weight loss or reversal of
metabolic illness via reduced eating.
Many of the drugs in Table 2 are stuck in phase 1 or phase 2 and do not move on
to phase 3 or clinical use. In most cases, this is not because of issues with safety; an
analysis of 2013-2015 clinical trials found that safety concerns sank ~25% of all drugs
undergoing clinical trials.

227,228

Instead the drugs never reach market either because of a

lack of demonstrable efficacy or a lack of a viable commercial market for the effects of the
drug.

1.3.3.2.
A historical perspective on weight loss treatment reveals insights
applicable to today
How is it possible that 100+ drugs, many with totally distinct mechanisms of
action, have been tested for weight loss, with no real advances? An examination of the
first attempts at medical therapy for weight loss may be useful to understand the
inherent problems with the approaches tried so far. Serious study into pharmacological
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treatment of obesity can probably be said to have started in the late 1930s, with high
protein diets (i.e. low carb, low fat), amphetamines, thyroid extract, and 2,4-dinitrophenol
all understood as potential weight loss agent and under intense scrutiny for their efficacy
229–231

. Much of the research conducted on these drugs at that time has meaningful

implications for the study of weight loss today.
One example, a retrospective cohort study published in 1949, is illustrative. This
study evaluated 299 patients who attended an outpatient weight loss clinic and divided
them into three treatment groups. The first was dietary intervention alone (1200
kcal/day), the second was diet + thyroid, and the third was diet + amphetamine sulfate.
The average amount of weight lost by group at the end of two months was 3.3, 2.3, and
3.1lbs respectively. At the end of treatment, the greatest weight loss was in the most
obese individuals who lost on average 9.1(over an average of 9 months), 10.4 (over an
average of 6.3 months), and 19.6lbs (over an average of 12 months) on average. This is
about the same amount of weight loss seen with the FDA approved drugs of today

222

.

Further, the clinical data for these agents show a similar exponential decay in the amount
of weight lost over time (i.e. they observed the same plateau as noted in dietary
interventions today, see section 1.3.1).

Researchers at the time noted each of these

weight loss strategies manipulated distinct aspects of the physiology regulating weight
232

. These included the following:

Increased basal energy requirement:
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1.

Decreased energy use efficiency: dinitrophenol (an oxidative phosphorylation decoupler discovered when ammunition manufacturers during WWI lost weight by
chronic inhalation of the chemical) 230,231,233

2.

Increased thermogenesis: thyroid extract and dinitrophenol.

3.

Reduced energy absorption: amphetamine (minor increase in gut motility)232

Increased voluntary energy expenditure:
1.

amphetamine

2.

exercise regimens

Decreased food intake:
1.

Reduced sensation of hunger: amphetamine

2.

Voluntary reduction in eating excess energy: diet and psychotherapy
The drugs in Table 2 can easily be fit into each of these categories. In particular,

many satiety agents targeting hypothalamic neuropeptide systems have been tested and
failed, which is particularly relevance to my work in Chapter 2 and Chapter 3 that
specifically does not emphasize this aspect of hypothalamic neuroscience. Because of the
current deluge of basic science publications on leptin-mediated satiety and increased
metabolic rate via hypothalamic nuclei, it is worth examining why leptin therapy fails to
control weight 234.
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1.3.3.3.
Satiety agents fail because of "satiety resistance" - generalizing
the case of metreleptin
Metreleptin is a synthetic analogue of human leptin that did not pass phase 2
trials for treatment of obesity after several attempts. It also failed to meaningful alter
long-term efficacy of glucose control (when paired with insulin) for treatment of T1DM
235,236

. Instead, it was FDA-approved in 2014 for treatment of several forms of

lipodystrophy associated with leptin deficiency 236.
Obesity and metabolic illness are generally considered to be diseases of insulin
and leptin resistance; even in T1DM

235

patients develop higher-than-population levels of

insulin resistance because of the exogenous insulin. Adding more ligand to these
receptors will only perpetuate the resistance mechanism in the long term. The natural
response to this problem is to develop some sort of sensitizing agent; multiple agents
that could potentially accomplish this were proposed in a recent review titled "Renaissance
of leptin for obesity therapy"

237

.

Many of them can be found in Table 2, either as

failed/stalled investigational drugs or ones with only modest efficacy in the clinical setting
such as liraglutide and metformin reviewed previously 237. This parallels the fact that these
agents have already been used as insulin sensitizing agents in T2DM, as have drugs like
the thiazolidinediones and SGLT2 inhibitors 87. The former has fallen out of favor clinically
for lack of efficacy and side effects and the latter seems to work by forcible reduction in
serum glucose rather than targeting the problem of insulin sensitivity directly.

48

This concept can be broadened: the failure of the myriad satiety-targeting (a.k.a.
anorectics) drugs in Table 2 should indicate the metabese person suffers from "satiety
resistance". Put another way, the primary driver of the eating habits that lead to obesity
and metabolic illness is not lack of satiety signaling. Instead, the overeating leads to
feelings of hunger. As described in section 1.2.4.2, much of the fasting research in the
1960s and 70s reported that patients who ate no food for months at a time often stopped
feeling hungry all together, until they reached substantial levels of protein catabolism.
A recent rigorous study of appetite in weight loss put individuals put on a VLCD
ketogenic diet for 8 weeks

104

. They had an average weight loss of 18kg (over 10% of

body weight loss, 10%WL) over 8 weeks (nearly double an FDA-approved drug's efficacy).
They had the worst level of hunger at day 3 of the diet, but which nearly returned to
baseline by week 9. However, during the next 4 weeks, they were introduced to a normal
diet, and hunger levels at the end of 4 weeks resembled the day 3 hunger. Notably, serum
GLP-1 was highest at baseline, second highest at week 13 (the very end), and lowest at
10%WL. Active ghrelin was suppressed throughout until week 13, when it nearly doubled.
PYY was also at its lowest at 10%WL, as was insulin (which paralleled GLP-1).
From the failure of satiety enhancers and evidence that many peripheral satiety
hormones do not necessarily correlate with reported appetite during rigorous monitoring
of patients undergoing weight loss (except for leptin), it can be concluded that it may not
be a deficit in satiety signaling that prevents people from maintaining diets. Instead, it
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may be the case they are eating foods for other reasons besides hunger, i.e. "satiety
resistance".

1.3.3.4.
Metabolic rate modulators and energy wasting drugs are
effective but too dangerous to give at sufficiently high doses
Metformin comes up repeatedly in the discussion of pharmacotherapy for
metabesity. It is unique in that it may be the best cellular mimetic of the fasting condition
available today. Perhaps ironically, it may also be an agent that most closely recapitulates
the effects of dinitrophenol (minus thermogenesis) without it's more deleterious side
effects.

Metformin's predecessor, phenformin, suffered similar side effects as

dinitrophenol related to mitochondrial toxicity, even though it acts on a different aspect
of mitochondrial ATP production and in the acute experimental setting has opposing
effects on the respiratory chain

233,238,239

. All three agents have been noted to be insulin

sensitizing agents, 240,241 and it even has been postulated that the issue with dinitrophenol
was that the doses used were too high and a reevaluation with smaller doses could meet
acceptable safety standards 233. It has recently resurfaced as an illegal weight loss agent in
the body-building community for this reason 233,242.
Metformin's effects are pleotropic and a single mechanism of action is not clear

243

;

however, a net effect of increased NAD+:NADH ratio appears to predict the effects. This
mimics cellular depletion of ATP and negative energy balance i.e. fasting

244

. This has been

borne out by many clinical studies that show, except for subjective feelings of fatigue,
muscle weakness, nausea, and diarrhea, metformin has few common side effects

245–250

.
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Probably because of the reduced efficiency of ATP utilization, there is concomitant
reduction in peak aerobic capacity and reduced adaptation to aerobic exercise training
25250–252 Nevertheless, its pleotropic effects on metabolic illness clearly resemble those
seen in fasting as described in Table 1. Metformin is broadly effective for metabolic illness
beyond reducing glucose levels; it induces weight loss

193,253,254

, corrects dyslipidemia and

hypertriglyceridemia 255–257, and even some evidence for blood pressure reduction

256,258,259

.

However, likely because it has very low potency (most drugs are dosed in the milligram
range whereas metformin is dosed in grams), metformin is rarely sufficiently effective to
be used as monotherapy.
Although thermionic compounds are experiencing a similar degree of excitement
as neuropeptide satiety modulators lately, they too have had predecessors that have
largely failed and were similarly plagued by patient toxicity 211.
In conclusion, it seems that current pharmacotherapy for weight loss and
subsequent treatment of metabesity is at an impasse. Satiety agents, no matter how
novel the mechanism, seem to have limited efficacy long term due to habituation and
resistance. Drugs that prevent nutrient re/uptake, reduce the efficiency of energy
utilization, or induce thermogenesis have upper limits to their dosage before toxicity or
malnutrition occurs, and this upper limit does not appear to produce substantial weight
loss.
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1.4.
To treat the metabesity epidemic, target the cause - acute-on-chronic
overeating driven by non-physiological factors
1.4.1. Early observations of non-physiologic drivers of hunger may still hold
promise today
Several times while preparing this dissertation, I have noticed the prescience of
early researchers and clinicians in the field of weight loss. When it comes to
understanding non-hunger and non-endocrine related eating behavior, the same has
held true. An influential primer by an gynecologist and endocrinologist, Dr. Charles Freed,
in 1947 describes what he believes are the "psychic factors" that drive overeating
(emphasis mine) 260:
There are a variety of psychologic factors which intensify the appetite for
food. Many of these are unconscious, while others are recognized by the patients
and can be controlled by them [...] Five hundred consecutive patients who
requested treatment for their overweight were asked the question "When you are
nervous or worried do you eat more or less?" [370 eat more, 130 eat when bored
instead, and the last eat all the time...] The following conditions, many of which are
capable of being treated by the general physician, have been found to result in
overeating.
1. Environment [growing up in families which eat excessively, businessmen who
eat rich foods commonly during meetings]
2. Economics [growing up poor makes food relatively insecure and hence one more
likely to overeat when given access, as well as how cheap food is high calorie]
3. Monotony [lack of interest or distractions or even mere inactivity, such as
staying at home at the weekend, leads to relative overeating]
4. Occupation [working in kitchens affords greater access to food]
5. Organic diseases [being bedridden does not alter the typical amount of calories
eaten per meal, despite reduced daily expenditure]
6. Nervousness.- That which makes a patient worried or anxious, such as a social
upset, domestic difficulty, or illness in the the family, will result in overeating [...] it
is not uncommon that after the death of a member of the family the others will find
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themselves getting heavier, much to their consternation and shame because loss of
weight is considered a classic response to such an occurrence.
7. Glandular imbalance [endocrine causes, typically rare]
8. Subconscious factors [Psychoanalytic-Freudian assessment ...]
Childhood and adult food environment and poverty map directly onto current
discussions of food deserts and the obesogenic American diet; for an article written in
1947, this is prescient

261–263

. Some of the other observations are prosaic, but Dr. Freed is

unique for describing, so clearly and explicitly, how people may use eating as a damper
on their emotions (anxiety, nervousness, and boredom alike). These drivers of eating
behavior remain poorly recorded in an experimental or systematic way until very recently
and almost exclusively come from psychology

264–266

. But, I believe the data in the other

chapters shows that such a focus on non-hunger-alleviating benefits of eating may be
fruitful for really targeting patient behavior.
Dr. Freed's psychoanalytic discussion, however, focuses on fairly esoteric concepts
of maturity and oral fixation. Perhaps because of this, a prominent psychiatrist sent a
letter to the editor of JAMA in response to Dr. Freed and stated the following 267:
The fundamental problem is whether emotional problems per se, even as
"inciting stimuli," cause obesity unless there is already an inherent, constitutional
disposition. The term "constitution" which clinicians consider primarily essential in
the problem of obesity, is never mentioned in Dr. Freed's article. His article conveys
the impression that a psychiatric approach to the emotional problems of the obese
individual [is the only important therapy]. This assumption, I feel, is not justified,
because the constitutional potential limits a priori psycho-therapeutic efforts.
These are questions discussed to this day, with many researchers adhering tightly
to genetic/epigenetic or alterations in basal metabolism "constitutional" factors

237,268

. Or,
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they may believe people who overeat do so because of irresistible hunger like that
described by the men in the MSE that resembles a reflex more than a complex behavior.

1.4.2. The state of emergency: a metabesity epidemic with no known way to
alter ACO in the long-term
The medical field has developed and is currently testing over 100 drugs (Table 2)
with mechanisms of action hitting nearly every known constitutional factor and nearly
every known satiety center, as well as all conceivable forms of dietary macro- and micronutrient intake modifications. We have only seen relentless increase in the prevalence of
metabolic illness (Figure 1). While the terminology and conceptual models used by Dr.
Freed are a bit outdated, his is the only therapeutic approach that has not been tested
with the full might of either basic science or clinical research. The "psychic" origins of
overeating are worth exploring in more detail.
In this chapter, I have endeavored to demonstrate the fundamental importance of
studying eating behavior and the non-homeostatic factors that may affect it. From the
data presented, I believe the following conclusions can be made:
1.

Metabolic illness is an epidemic that is the causal origin of most chronic diseases
(1.1. and Figure 1)

2.

Acute-on-chronic overeating – that is, the act of eating excess calories on top of the
obese state produced by overconsumption – is a necessary causal factor in the
expression of metabolic illness , as demonstrated by short-term fasting (1.2., Table 1,
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and Figure 2). Thus, changing eating behavior is crucial not only for obesity, but for
most metabolic diseases,
3.

Diet and lifestyle interventions for weight loss are successful, but fail in the long
term primarily because of patient relapse, rather than adaptive thermogenesis or
metabolic changes not proportional to lost weight. Further, bariatric surgery is
effective primarily because it forces diet adherence or simple calorie malabsorption
(1.3).

4.

No long-term, meaningfully effective weight loss drug has been developed,
despite intensive targeting of satiety, thermogenesis, energy utilization efficiency, and
nutrient absorption. Further, these concepts are not new and have been targeted
since the 1940s, without any increase in success (1.3.3, Table 2)

5.

The common thread uniting these findings and more than 70 years of research on
eating behavior is this: there are untreated behavioral drivers of overeating that are
not related to the physiology of energy balance. Discovering these drivers and a
mechanistic basis for them (rather than the psychoanalytic model as done by Dr.
Freed) may finally give credibility to this concept and provide truly new avenues for
treatment.
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1.5.

Conclusion

1.5.1. A new neuroscience of overeating in the model of the neuroscience of
addiction
It is in light of the above observations that I became intensely interested in
understanding the basic neurocircuitry regulating the interaction between hunger and
other internal states. It appears that the fields of behavioral and pharmacological
therapies for sustained and effective weight-loss, and by proxy, metabesity, need to
target novel drivers of eating behavior. Further, it appears that some of these drivers are
derived from affective (i.e. emotional) experiences like anxiety, stress, and depression. For
example, in the 1947 review cited earlier, Dr. Freed expressed a conundrum that strikes us
as odd even today "after the death of a member of the family the others will find themselves
getting heavier, much to their consternation and shame because loss of weight is considered a
classic response."
Dr. Freed’s report indicates the possibility that eating is used as a method to
suppress the negative aspects of other affective experiences, even though eating itself
has consequences. Certainly, one repeated observation in Chapter 1 has been that
human beings are not behaving the way we should over time. We continue to override
internal satiety signals, mental plans, and external social pressures to continue to
consume food. In psychiatry, "stress eating" and "food addiction" are controversial
concepts; however, the use of food as a way to reward oneself and reduce anxiety is
commonly observed. Clinically, patients with binge eating disorder uniformly report stress
as a trigger for eating

. Even more intriguingly, most drugs that reduce clinical levels of
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anxiety, such as atypical antipsychotics, tricyclic antidepressants, beta-blockers,
benzodiazepines, marijuana, and alcohol, generally increase eating behavior and
chronically can lead to weight gain 270.
The concept of stress eating seems quite similar in expression to the concept of
"self-medication", wherein people suffering from mental illness, typically depression,
begin using drugs like cocaine or alcohol specifically as a way to feel better

271

. The

common pathway for clinically-identifiable addictive behaviors is the heightened increase
in activity of opioid receptors, most easily accessed by increased ventral tegmental area
(VTA) release of dopamine in the nucleus accumbens (NAc) in such a way as to bias for
D1R activation/expression

272

. However, in this case, there was a conscious choice to use

the drug for the amelioration of psychiatric symptomatology (depression may represent
an abnormal extended blunting of this neurocircuits activity), rather than purely for
euphoria.
It is reasonable to ask whether these hypotheses of non-physiologic drivers of
eating behavior have been targeted directly by behavior therapy. Currently, there are
many diets of every macro- and micronutrient composition and calorie content. Further,
there are also some behavioral therapies for overeating that are derivatives of addiction
therapy - these target reward-seeking behavior or employ behavior change techniques
like motivational interviewing. These all have some degree of efficacy, and produce
171,220

significant effects in certain subsets of patients
portion control has also shown some efficacy

. Targeting mindless eating through

273

. However, to my knowledge, no clinically
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common weight loss program has targeted replacing the unique suppressive role eating
may have on the experience and expression of other affective states like anxiety or
depression. Yet, stress, depression, and unemployment are predictors for poor adherence
to weight loss regimens of all kinds 172.
The reason that this correlation has not been targeted directly for improvement of
adherence to weight loss regimens may be because of a lack of mechanistic evidence that
this correlation is relevant. Indeed, the non-hunger drivers of eating behavior described
above - stress eating and anxiety reduction – do not yet have an expansive mechanistic
literature demonstrating how they might operate at the neurocircuit level. It is worth
noting that this approach has already paid dividends in the excellent work that produced
the neurocircuit theory of addiction. For example, it is not intuitive that opioid receptor
antagonists like naltrexone would be effective at reducing alcohol-consuming behavior.
However, this treatment was tested and is effective because of the demonstration that
addictive behaviors require the interaction of GABA, dopamine and opioid release in the
nucleus accumbens 274.
Thus, it is my hope that by leveraging the neurocircuit approach pioneered to
understand and treat addictive behavior, a similar approach will be fruitful in the new
neuroscience of eating and provide avenues for new therapy, both pharmacologically and
behaviorally.

58

1.5.2. Example neurocircuit evidence underpinning the possibility that
hunger and eating may alter the expression of other affective states
A neurocircuit basis for the interaction between hunger and other affective states
such as anxiety will expand the field of metabesity therapy. Amidst many publications on
the primary neurocircuitry of hunger, some interesting data on how hunger alters the
expression of other affective states has also been revealed. However, interpreting much
of this data has been challenging because of the confounding effects of the typical
experimental manipulations used to elicit hunger behavior (i.e. fasting).
For example, it is well established that hunger and eating behavior reduce mouse
expression of anxiety

275

. However, this finding is derived from observations of the fasted

state and is difficult to distinguish from a negative drive to find food. Further, it has so far
been difficult to determine if, when comparing between physiological hunger (often
called homeostatic) and non-physiological eating (often called hedonic), the latter is only
driven by traditional reward circuitry

276,277

or has unique pathways that may underpin it.

This is a crucial question for separating whether all non-physiologically driven eating
behavior is driven by ‘food addiction’, or whether hunger and eating can directly alter the
experience and expression of affective states.
One way to demonstrate the difference is to test a relatively reward-neutral
behavior, like maternal care, and examine whether neurocircuits exist that connect the
circuits driving eating behavior and those driving maternal care. In a recent Journal of
Neuroscience publication (Li et al. 2019), the investigators demonstrated this point

278

. In
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this study, the investigators used optogenetics to activate hypothalamic arcuate AgRPexpressing neurons that project to the hypothalamic median preoptic area (MPOA) in
mouse dams (mothers with pups). They demonstrated the following: 1) protracted fasting
reduces maternal nest building and increases the latency to scattered pup retrieval 2) the
AgRP-->MPOA projections are GABAergic 3) activating this projection prevents maternal
nest building, but not pup retrieval 4) a different set of MPOA neurons underlie pup
retrieval than do nest building. This data provides a unique glimpse into how eating
behavior and care behavior interact with each other, disrupting complex expressions of
affective state. Further, it demonstrates this occurs directly, without relying upon
interaction with traditional drivers of reward behavior like the ventral tegmental area or
nucleus accumbens.
Given this fascinating neurocircuit finding that two very distinct behaviors appear
to 'compete' in real time, with electrophysiological evidence that this occurs via
monosynaptic connection, it is natural to wonder if such direct competition can be
observed and tested in other circuits. Indeed, research in the Tong laboratory, which will
be discussed more extensively in Chapters 2 and 3, also has demonstrated the
competition between hunger and aversion driven purely by subcortical circuits, where
neuroanatomcial areas known to generate these aversive behaviors such as selfgrooming directly synapse and act on hunger areas – and vice versa 281,282.
If it is true that 1) the act of eating elicits activation of certain brain regions
associated with hunger more generally and 2) direct projections from those brain regions
60

activate or inhibit other brain regions that are associated with anxiety, these data would
provide a mechanistic platform for the context of "stress-eating" and have all the
implications described in Section 1.5.1. My work in Chapters 2 and 3 discusses my small
addition to the suite of evidence showing that eating and anxiety-linked brain regions do,
in fact, directly interact with each other, independent of physiologic hunger.
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Chapter 2. A lateral hypothalamus to basal forebrain neurocircuit promotes
feeding by suppressing responses to anxiogenic environmental cues

This chapter is based upon: Cassidy RM, Lu Y, Jere M, Tian JB, Xu L, Mangieri LR,
Felix-Okoroji B, Selever J, Xu Y, Arenkiel B, Tong Q. A lateral hypothalamus to basal
forebrain neurocircuit promotes feeding by suppressing responses to anxiogenic
environmental cues. Science Advances 2019 5:eaav1640

Relevant Science Advances Original Author License to Publish policy: Author
also retains the non-exclusive right to use the Work in the following ways without
further permission but only after publication of the Work by AAAS and subject to
the requirement that credit be given to its first publication in the appropriate issue
of the applicable Science journal: 1) Reprint the Work in print collections of
Author's own writings; 2) Reprint the Work in print format for inclusion in a thesis
or dissertation that the Author writes.
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2.1.

Rationale
Given the information presented in Chapter 1 it becomes clear that identifying

hunger and eating neurocircuits driving or suppressing non-hunger affects will yield new
behavioral

approaches

to

treating

acute-on-chronic

overeating.

There

are

an

extraordinary number of subcortical targets to examine that may bear fruit, and it is clear
that the mammalian brain is possessed with an abundance of redundancy such that any
single anatomical nucleus is not the sole arbitrator of most functions. However, the
hypothalamus and lateral hypothalamus (LH) in particular may prove to be important
nodes in the neurocircuits that produce these functions.
Hypothalamic neurocircuits are developmentally programmed and highly distinct
in

their

ontogeny;

disruption

of

individual

hypothalamic

development can cause lasting changes in eating behavior

neurocircuits

279–281

during

. There is mounting

evidence that some of the known genetic disorders that lead to overeating such as
Prader-Willi syndrome, have prominent disruption of hypothalamic neurocircuit
development – further, treatment with neuropeptides produced in the hypothalamus like
oxytocin has been effective for regulating eating behavior in that condition

200,282

. The LH

sits at the center of a large number of functionally integrated affective systems that have
been identified in a diverse set of experimental conditions, receiving input from the
ventral pallidum, central amygdala and basal nucleus of the striatal tract (BNST), and
prefrontal cortex

. The LH has many diverse functions and projections, as will be

283,284

discussed below; however, few of its outputs regulate motor output directly. Instead, it
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alters the activity of other nuclei that integrate this input with other input before
generating motor output 283–285. This is consistent with the hypothesis that its primary role
is to generate an affective state and alter the expression of other affective states.
Thus, hypothalamic neurocircuits in general, and LH neurocircuits in particular, are
promising targets for investigating major nodes connecting the hunger and eating to
expression or suppression of other affective states. Previous work in the Tong laboratory
has indeed discovered such neurocircuits, defined by fast neurotransmitters and
neuropeptides both, which mediate the intersection between peripheral signals of energy
balance and the central nervous system

286–294

. In particular the Tong laboratory has

demonstrated that the lateral hypothalamus (LH) sends both GABAergic and
glutamatergic projections to the paraventricular hypothalamic nucleus (PVH). Activation
of the former cause feeding and the latter cause self-grooming, a common rodent marker
of anxiety

286,294

. In addition to this projection and the LH-basal forebrain projection I

describe below, at the present date the LH has been demonstrated to send GABAergic
projections to the ventral tegmental area (VTA)
ventrolateral preoptic area
terminalis (BNST)

302,303

299,300

295–297

, periaqueductal gray (PAG)

, dorsal raphe nucleus (DRN)

, locus coeruleus (LC)

299

301

298

,

, bed nucleus of the stria

, and tuberomammillary nucleus (TMN)

299

.

Crucially, it appears that GABAergic outflow is responsible for eating behaviors, whereas
glutamatergic outflow is anoretic

304,305

. While not all of these GABAergic circuits have

been tested extensively, activation of the LH-VTA, LH-PVH, and LH-BNST circuits induces
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robust feed behavior, activation of the LH-PAG drives attack, and those to the LH-VLPO
induce awakening from sleep.
This diversity of functions demonstrates well that the LH is highly heterogeneous,
even within the subset of LH neurons that release GABA. There is also abundant evidence
for functionally distinct subsets of LH neurons that synthesize glutamate, dopamine,
galanin, hypocretin/orexin (orexin), melanin concentrating hormone (MCH), dynorphin,
enkephalin, neurotensin, cocaine- and amphetamine regulated transcript (CART),
parvalbumin, thyrotropin releasing hormone (TRH), corticotropin releasing hormone
(CRH), nociceptin/orphanin FQ, and unocortin-3

306,307

. Further, many of these

neurotransmitters and neuropeptides are co-expressed and co-released, and it is unclear
to what extent their projection patterns diverge. Some progress has been made in
identifying anatomical subdivisions within the LH (i.e. some studies refer to the
perifornical region, the posterior LH, and the anterior LH) that may have distinct
functions, but it generally remains difficult to conclude whether the region determines
the projection or cellular type determines the projection

284

. This may explain why there

has been relatively little success in studying this region using genetic markers as there
has been for other brain regions. The primary exception to this, of course, is work on the
sleep-wake cycle driven by orexin and MCH neurons

308

; these are regionally segregated

within the LH and mostly do not co-localize with other neurotransmitters. By comparison,
calcium imaging of LH GABAergic neurons has revealed that adjacent GABAergic cell
bodies have distinct activity patterns during the feeding process; some are active only
65

during food approach, some are active only during food consumption, some are active
during both, and some are not activated in either condition

305,309

. Do these adjacent

neurons target distinct regions? It is not yet known and will require intensive study to do
so.
Studying specific projections instead remains one of the most effective ways to
examine what behaviors each subset of LH GABA neurons mediates. Of particular relevance
to the question of how eating interacts with anxiety is the projection of the LH to the
medial septum (MS) and diagonal band of Broca (DBB), which for the purposes of brevity
will be referred to as the DBB or basal forebrain (BF). The DBB shares strong reciprocal
connections with the primary sensory cortex, the thalamus, and activation causes
behavioral inhibition and enhanced attention to the environment

299,310–313

. Conversely,

destruction of the DBB or BF more generally appears to cause generalized behavioral
disinhibiton, including excess eating and drinking 314–317.
The existence of an LH-DBB projection has been controversial, as it has variously
been reported as present and absent within the older tracing literature

318–321

. This likely

reflects the underlying heterogeneity of the LH discussed earlier. Orexin activity in the BF
drives wakefulness and LHorexin neurons are documented to project to the BF

322,323

. Viral

retrograde tracing from the MS/DBB portions of the BF has shown that LH neurotensin
project to this area, and that the LH sends input to cholinergic neurons

324

313

. However, no

connection related to feeding behavior has yet been identified prior to this work and the
putative LHGABA-BF circuit has not been discussed in reviews of this aspect of LH
66

neuroscience

304,306

. A major joint publication with our collaborators wherein it was

demonstrated that destroying cholinergic neurons within the DBB induces profound
obesity and chronic activation causes starvation and death

325

, lead to this hypothesis: LH

projections to the basal forebrain drive feeding behavior. Further, I hypothesized that this
likely related to some aspect of reducing responsiveness to the environment as activation
of the BF broadly increases alertness and attentional modulation of sensory processing
322

. To test these hypotheses, I used the materials and methods in section 2.2.
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2.2.

Materials and Methods
The following tools were selected as they were best suited to answer the questions

posed in Section 2.1. They provide the ability to both manipulate (via optogenetics) and
observe the activity of (via fiber photometry) specific, molecularly defined neurocircuits in
real-time and in freely moving mice. Since the mice are tested in real-time and are freely
moving, they can be tested using standard behavioral neuroscience techniques such as
the open field test or elevated plus maze. The acuity of effect also allows pre- and postintervention comparisons, as well as paired comparisons across two different
interventions (e.g. a refeeding assay paired with or without laser stimulation, described
below), all in the same animal. This reduced the effect of inter-subject variation. The
relatively large effect sizes produced using these techniques increased the power of these
tests. This made it possible to minimize the number of mice used, in keeping with IACUC
goals to minimize potential pain and suffering of experimental animals.
Given that many of these experimental techniques are used and reused across
several different experiments and questions, the Results section has been written to
integrate the use of these techniques into a logical and cohesive story.

2.2.1. Mouse care and strains
All experiments were performed with genetically modified mice. These mice were
housed inside the semi-barrier animal facility located inside the Institute of Molecular
Medicine, part of the University of Texas Health Science Center at Houston (UTH). After
weaning at 3 weeks of age, between 2 to 5 littermates were group-housed in cages with
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corncob bedding. They were fed ad libitum with access to standard pelleted laboratory
mouse diet (referred to here as chow) and water. The vivarium was kept between 21-22℃
and has a 12-hour light/dark cycle. All animal care and procedures were approved by the
UTH Institutional Animal Care and Use Committee (IACUC) and all guidelines for care and
use were followed.
Preliminary analysis demonstrated no meaningful difference in elicited behaviors
between males and females, so these were both used in roughly equal numbers. Multiple
litters of mice were used for testing and mice were at least 6 weeks old prior to any
behavioral testing. The following genetically modified strains of mice were used: Pdx1-Cre
292

, Vgat-Cre

326

, and Vglut2-Cre

326

. The details of how these mice were generated may be

found within the references; they were derived from C57BL/6 and 129 mouse strain
crosses. In order to reduce the possibility of a strain effect, nearly all experiments
discussed in the Results section were performed with internal comparison of an acute
gain-of-function intervention (such as activating a neurocircuit, discussed below).
Pdx1-Cre is a transgenic mouse line where expression of Cre is dependent upon
expression of the pancreatic-duodenal homeobox 1 (Pdx1); Cre is expressed in the
pancreas, and in the medial preoptic area, arcuate nucleus, dorsomedial hypothalamic
nucleus, DRN, inferior olivary nucleus, and in the LH

292

. This limited expression of Cre in

the brain makes it easier to reduce off-target expression of cre-dependent proteins after
viral infection. Vgat-Cre is a knock-in mouse line where ires-Cre has been inserted just
downstream of the SLC32A1 gene (which encodes for vesicular GABA transporter/Vgat)
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326

. The internal ribosome entry site (IRES) gene sequence allows translation initiation at

that site on the mRNA

327

. The net effect is that Cre is expressed at the same level and in

the same tissue as Vgat, allowing targeting of GABAergic neurons. Vglut2-Cre is also a
knock-in mouse line, with ires-Cre inserted downstream of SLC17A6 (encodes for vesicular
glutamate transporter 2/Vglut2) such that only tissue that expresses vglut2 (a subset of
glutamatergic neurons that are the predominant type in the hypothalamus and basal
forebrain 326,328.

2.2.2. Neurosurgery
Stereotaxic surgery for the delivery of viral vectors to localized brain regions and
for optical fiber implantation was performed as previously described in work from the
Tong Lab, with 0.1-mm precision in the anterior-posterior (AP), mediolateral (ML), and
dorsal- ventral (DV) axes

286,294

. Mice were anesthetized with a ketamine, xylazine,

acepromazine cocktail (80, 8, and 2.5 mg/kg); after confirmation of the absence of the
pedal reflex, mice were affixed into the stereotaxic frame, and skin over the cranium was
incised. Viral vectors were delivered with a 0.5-µL syringe (Neuros Model 7000.5 KH, point
style 3;Hamilton, Reno, NV, USA) with the infusion rate controlled by a micro-injector
motor (Quintessential Stereotaxic Injector; Stoelting, Wood Dale, IL, USA) between 25 and
50 nl/min. Viral preparations were titered at ~1012 particles/ml. Coordinates for injection
were as follows: AP −1.5, ML −0.9, and DV −5.1 (for LH); AP +1.1, ML −0.1, and DV −5 (for
DBB). For optogenetic experiments, an uncleaved fiber optic cannula [Ø1.25-mm stainless
ferrule, Ø200-µm core, 0.39 numerical aperture (NA); Thorlabs, Newton, NJ, USA] was cut
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to 4.8 to 5.0 mm in length for implant over the BF. For fiber photometry, a precleaved
wide-aperture fiber optic cannula (Ø1.25-mm stainless ferrule, Ø400-µm core, 0.66 NA;
Doric Lenses, Quebec, QC, Canada) were implanted over the LH or BF. For GABAzine and
saline in vivo micro-infusions, a guide cannula was placed over the BF, which permitted
preinjection of drug, before placing a removable optic fiber. Fast-drying acrylic glue and
then dental cement were used to secure implantation before suture. Two injections of
carprofen (5 mg/kg) were administered after surgical analgesia, 24 hours apart. All LH
injections were unilateral since preliminary data showed no difference between right and
left activation; BF injections were centrally located (with 0.1-mm right shift to avoid
penetration of the superior sagittal sinus) and thus bilateral.

2.2.3. Viral vectors, plasmids, and Cre-dependent protein expression
A core aspect of these experiments is the use of viruses that deliver plasmids to
neurons. Those plasmids encode for the machinery necessary to initially package the
virus, a mammalian promoter sequence, in this case, elongation factor 1 alpha (Ef1α), and
a protein of interest. In most cases, there is also a genetic construct that makes
expression of the gene Cre-dependent.
Cre (Causes Recombination) is a bacteriophage enzyme used to excise integrated
viral DNA through recombination

329

. It does this by finding two recombinase recognition

sites that match a specific DNA sequence template like loxP1 (locus of excision P1), then
recombine them so that the 3' end of the first site and 5' end of the second site are
connected in a circular piece of excised DNA. However, if one of the loxP1 sequences is
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inverted, Cre will actually invert the gene instead of excise it. Further, if two different loxp
sequence types are used, Cre recombines by the matched sequences (this study uses
vectors with loxP1, loxp2272, and fas sequences) . A specific combination of two sets of
loxp sites (loxP1 and loxp2272) in the inverse orientation, called the flip-excision (FLEX)
switch or double inverse orientation (DIO) cassette causes the following effects

330

: Cre

binds one set and flips the gene into the sense position; this also causes the internal loxp
site on the pair not used to be uninverted and in the forward position. Then, Cre binds the
forward position loxp sites, which flanks one of the original paired loxp sites, and cuts
that sequence out. Now, the gene is stable in the sense position. This results in Credependent expression of the protein. It is also possible to use the opposite approach with
a simple loxp-site flanked protein of interest in the sense position - allowing a mixture of
Cre-Off and Cre-On protein expression 331.
Using the mouse strains and neurosurgical techniques described above, this
allows both anatomical and molecular specificity in the introduction of new proteins to
the mouse genome. The primary proteins of interest used in this study are:
channelrhodopsin 2 (ChR2)

332

, which is a blue-light sensitive non-selective cation channel

that depolarizes neuronal membranes to cause action potentials; hm3dq (or GqDREADD)
333

, which is a muscarinic acetylcholine Gq protein-coupled receptor derivative only

activated by a synthetic drug, clozapine-N-oxide (CNO); and GFP-calmodulin protein 6
(GCaMP6m), a fusion of the Green Fluorescent Protein (GFP) and Calmodulin that
increases in fluorescence intensity at higher intracellular calcium levels

334,335

. For synaptic
72

tracing, synaptophysin fused to GFP allows localization of synapses with GFP and largely
avoids the issue of mistaking fibers of passage for synaptic input

336

. For retrograde

tracing, I used two methods. First, I used a mutated version of the adeno-associated virus
(AAV) viral vector, called rAAV2-retro, which is presumed to enter into neurons only at the
presynaptic terminal and be transported to the nucleus

337

. rAAV2 allows retrograde

tracing; the version I used has a plasmid containing a histone protein fused fluorescent
protein (H2B::Venus) such that only the nucleus of the presynaptic neuron expresses GFP.
It also contained an enhanced version of Cre, called iCre. Finally, I also used a viral vector
containing FLEX-TVA-mRuby and another one containing FLEX-EGFP to use for Credependent fluorescent labeling of neurons for electrophysiology.
The following plasmids were packaged in viral vectors by either the Baylor College
of Medicine Neuroconnectivity Core (with special credit to Dr. Benjamin Arenkiel for
assisting us in procuring them) or by commercial sources with the catalog number as
indicated. The viral capsid serotype was either mixed AAV 2/9 or DJ/8 unless otherwise
indicated.
•

AAV-Ef1α-FLEX-hChR2(H134R)-EYFP-WPRE-hGHpA (Addgene, 20298)

•

AAV-Ef1α-FLEX-hChR2(H134R)-EYFP-WPRE-pA (Univ.of North Carolina Vector Core)

•

AAV-Ef1α-FLEX-EGFP-WPRE-pA (Baylor Neuroconnectivity Core)

•

AAV-Ef1α-FLEX-Syn::EGFP-WPRE-hGHpA (Baylor Neuroconnectivity Core)

•

AAV-Ef1α-FAS-ChR2(H134R)-mCherry-WPRE-pA (Addgene, 37090)
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•

AAV-Ef1α-FLEX-TVA-mRuby (Baylor Neuroconnectivity Core)

•

AAV-EF1α-DIO-GCaMP6m-WPRE-pA (Baylor Neuroconnectivity Core)

•

AAV-Ef1α-DIO-hM3Dq-pA-mCherry (Baylor Neuroconnectivity Core)

•

(capsid AAV2/1) AAV-Ef1a-EGFP-2A-iCre (Baylor Neuro- connectivity Core)

•

(capsid rAAV2-retro)AAV-Ef1a-iCre-P2A-H2B::Venus (Baylor Neuroconnectivity Core)

2.2.4. Ex vivo brain slice electrophysiology - ChR2 assisted circuit mapping
NOTE: while I was present during the majority of electrophysiological recordings,
patched a few neurons myself, and performed all surgeries and post-hoc statistical
analysis, the large majority of recordings were performed by a post-doctoral fellow in the
Tong Lab, Yungang Lu, PhD.
Coronal brain slices (250 to 300 µm) containing the DBB (centered around the
ventral portion) were harvested from Cre+ mice at least 3 weeks after unilateral LH
injection of AAV-FLEX-ChR2-EYFP or AAV-FAS-ChR2-mCherry. After inhalational anesthesia
of isoflurane, mice were decapitated and brains were quickly harvested and preserved in
ice-cold cutting solution. After slicing, the brains were incubated in 32°C artificial
cerebrospinal fluid (aCSF) for an hour and then maintained at room temperature until
used for recording. aCSF composition was as follows: 125 mM NaCl, 2.5 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, and 10 mM d-glucose, bubbled
with 95% O2/5% CO2. During recording, slices were superfused with aCSF (2 ml/min)
warmed at 32°C (feedback-controlled in-line heater TC-324B, Warner Instruments). Cells
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were identified through a 40× water-immersion objective with differential interference
contrast and infrared illumination. DBB neurons were selected for recording if found
medial to the islets of Cajal and below the horizontal midline and recording for the
presence or absence of cre-dependent fluorescence in the pertinent experiments. Wholecell voltage-clamp recordings were made using patch pipettes (3 to 5 megohms) filled
with Cs+-based low internal Cl- solution, containing 135 mM CsMeSO3, 10 mM Hepes, 1
mM EGTA, 3.3 mM QX-314, 4 mM Mg–adenosine triphosphate, 0.3 mM Na2–guanosine
triphosphate, and 8 mM Na2-phosphocreatine (pH 7.3 adjusted by CsOH; 295 mOsm). For
ChR2-assisted circuit mapping, 473-nm laser light (Opto Engine LLC, Midvale, UT, USA)
was pair-pulsed onto the DBB at 1 to 5 ms). When an inhibitory current (IPSC) was
identified (no excitatory currents were identified), GABAzine (10 µM) was bath-perfused to
block GABA-A receptors and eliminate the current. After recovery, tetrodotoxin (0.5 µM;
Alomone Labs, Jerusalem, Israel) then 4-aminopyridine (100 µM; Acros Organics, Fisher
Scientific, Pittsburgh, PA, USA) was bath applied. The tetrodotoxin blocks conduction of
action

potentials

in

local

neurons,

preventing

non-light

induced

release

of

neurotransmitter at the synaptic cleft. The 4-aminopyridine blocks K+ channels that
normally respond to depolarization within the presynaptic neuron. The goal is to block
polysynaptic effects while enhancing optogenetically-mediated neurotransmitter release
to demonstrate a monosynaptic connection.
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2.2.5. Behavioral Testing
All tests were conducted during the light cycle after at least 3 weeks of recovery
from surgery in clean empty cages without bedding. For optogenetic feeding
experiments, an integrated rotary joint patch cable connected the ferrule of the
implanted optic fiber to the 473-nm diode-pumped solid-state laser (Opto Engine LLC,
Midvale, UT, USA). Light pulse protocol (10 Hz with 50-ms pulses at ~10 to 15 mW/mm2
was selected empirically on the basis of feeding data) was generated by a Master-8 pulse
stimulator (A.M.P.I., Jerusalem, Israel). For the RTPP test, OFT, and competing choice
feeding as- says, the laser activity was routed through a Noldus EthoVision XT (Noldus
Information Technology, Wageningen, Netherlands) behavioral chamber camera;
EthoVision XT 11.5 software was used to control laser activity dependent on mouse
position

2.2.5.1.
Feeding Behavior Assays A: discussion of "normal" laboratory
mouse behavior
Often discussions of overeating and undereating, particularly in mice, are difficult
to interpret without some familiarity as to what typical feeding behavior actually looks
like. Thus, this section is dedicated to understanding what ‘normal’ is for a lab mouse with
regards to eating.
The following represents a brief overview of considerations when evaluating
mouse eating behavior and the typical diurnal pattern of a laboratory (lab) mouse eating.
Lab mice come in a wide variety of strains, some of which have much greater potential to
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develop metabolic disease or to starve on a 'normal' rodent diet than others

338

. The mice

used in our experiment are typical for lab mice (derivatives of C57BL/6 and 129) Further,
lab mice are typically fed only a single food that has complete nutrition. Further, they
usually have minimal enrichment of their cage besides nesting material and several other
cage mates. Finally, the environment is tightly controlled - there is minimal variation in
the temperature, humidity, or light cycle duration

339

. Thus, most detailed analyses of

feeding behavior across multiple days in lab mice reflect extremely basic, entrained
patterns. This has a benefit for reductive simplicity, but also does not allow expression of
compensatory strategies that could alter eating behavior. For example, most lab mice do
not have an easy way to engage in voluntary energy expenditure that, if it were available,
may cause them to increase meal size or feed more frequently.
With this caveat, lab mice demonstrate the following diurnal pattern of behavior
340

. Mice are nocturnal. When entrained on a 12 hour light cycle, mice typically 'wake up'

(have no more protracted bouts of immobility, they move around even at night) around
15-30 minutes prior to lights off. The first feeding bout begins immediately and lasts
around 3 minutes and is followed by a water drinking bout the large majority of the time
340

. A study of food intake across three diets of high carbohydrate, high fat, or high

protein provides some useful bounding parameters 341. First, the number of feeding bouts
per day was 38, 33, and 48 respectively. The amount of kilojoules (kJ) consumed per bout
was at 1.2, 1.4, and 1.01 respectively. The average inter-bout period was 30, 40, and 25.9
minutes respectively. And finally, the total daily energy intake was 46, 43, and 48kJ
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respectively, with no statistical difference across dietary conditions. This is consistent
across methods for analyzing mouse behavior 342.
Work on the role of circadian clock genes in feeding behavior has demonstrated
that feeding bouts are largely restricted to the dark period, with a high likelihood to
concentrate around the time immediately after lights off and right before the lights on
period

343

. Notably, in the all-dark condition, feeding retains

its diurnal rhythmicity;

conversely, restricted access to food to short periods of time during the day can sustain
molecular clock expression rhythmicity or the downstream rhythmicity of activity
normally attributed to the clock

344

. In summary, mice tend to eat several times per hour

throughout the entire lights off period, while only consuming a small amount of food per
bout. Having established the general parameters of feeding, we can next explore the
behaviors preceding, during, and following a single feeding bout.

2.2.5.2.
Feeding Behavior Assays B: the ethological action map of a single
feeding bout in the mouse
Unfortunately, the word 'micro-structure' as it relates to feeding behavior has
largely been used in reference to the diurnal pattern of eating behavior (number of bouts,
size of bouts), and not the structure of feeding. So, instead, I have elected to incorporate
the phrase "ethological action map", derived from the set of motor movements that
typically appear together in coordinated complex action to accomplish ethologically
relevant tasks

345

. Here, I will describe the ethological action map of mouse free feeding

346

. Currently, automated analysis of complex mouse behavior - computational ethology -
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is only just starting to become standardized and widely implemented

347

. Thus,

quantitative analysis of such behavior is lacking. However, from the detailed action maps
provided by Whishaw 349,351–353, my own unpublished video recordings of free-eating
behavior in mice without experimental intervention, the Behavioral Satiety Sequence
(BSS) cluster of behaviors commonly used in pharmacological research, 354,355 and
grooming behavior analysis, 356 I propose the behavioral modules engaged during
feeding are as depicted in Figure 4.
Delineation of this sequence is useful, because it reveals how many different
behavioral tasks are accomplished before feeding behavior is successfully completed.
Interruption of any of these tasks can alter feeding behavior - and in truth, this is
probably why nearly every intervention made on the behavior of experimental models
produces some alteration in feeding behavior and overall weight gain.
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Figure 4. The anatomy of a single feeding bout - an ethological feeding action plan
for the mouse.
Demonstration of the series of behaviors and their triggers that a mouse engages in
before, during, and after a feeding bout. This is an ethological action plan for feeding at the
behavioral state level rather than locomotor level. Its utility is understanding the drivers and
inhibitors of feeding behavior in a systematic way. This is the uninterrupted eating bout: novel
stimuli or intermittent threat scanning can interrupt any phase of the eating bout.
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2.2.5.3.

Feeding Behavior Assays C: experimental techniques

Unless otherwise specified, mice were fed ad libitum in their home cages with
standard pellet chow in their home cage before testing. All mice were previously exposed
to HFD (Research Diets D12492; 20% protein, 60% fat, 20% carbohydrate, 5.21 kcal/g) in
their home cage several days before tests with HFD. For Pdx1-cre mice, the amount of
food consumed over a 15-min laser stimulation period was compared between FLEXChR2–transfected and FLEX-GFP–transfected mice. For Vgat-cre, amounts of food
consumed per mouse over a 10-min prestimulation period, 10-min laser stimulation
period, and 10-min post–laser stimulation period were compared. To determine food
preference, mice were given free access to both regular chow and HFD during a 10-min
laser stimulation period. To test competing preference for laser versus food, mice were
habituated to the Noldus chamber for 10 min with laser paired to one side of the
chamber and then, one of two paradigms was used: (i) regular chow was placed in laser
on side, and HFD was placed in the laser off side; and (ii) regular chow was placed in the
laser off side, and no food was placed in the laser on side. Latency to food consumption
was calculated as the time spanning from the beginning of food exposure after a 24-hour
fast or onset of laser stimulation and the first time the mouse bit the pellet.

2.2.5.4.

Pharmacology

GABAzine or saline (~200 nl) was infused into the DBB via a guide cannula. The
dose is comparable to other microinjection techniques targeting the basal forebrain in
mice 316. After 15 min, an optic fiber connected to a cap was fixed into place into the guide
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cannula, and laser stimulation pulsed. For diazepam experiments, mice were
intraperitoneally injected with either saline or diazepam (3 mg/kg) dissolved in 0.1%
carboxymethyl cellulose at 1:10 dilution of stock dissolved in dimethyl sulfoxide (DMSO)
and then placed into testing cage; timing began immediately after injection, with regular
chow (ad libitum fed state) or regular chow and HFD (fasted state) placed into the testing
cage with water. Food consumption was measured after 2 hours.
Two mouse models were used for the clozapine-N-oxide (CNO) experiments. 1)
Vgat-cre with LHFLEX-ChR2 and DBBDIO-GqDREADD, and Vglut2-cre with LHFas-ChR2 and DBBDIO-GqDREADD.
In both cases non-glutamatergic (i.e. GABAergic et al) neurons in the LH express ChR2,
and either GABAergic or glutamatergic neurons in the DBB express GqDREADD. Both had
an optic fiber implanted over the DBB. These mice then received intraperitoneal injection
of either saline or CNO (3 mg/kg at 1:15 stock solution in DMSO then dissolved in normal
saline) and left in a testing chamber for 30 minutes prior to onset of assay. Food intake
during this time was measured, then mice were exposed to 10 minutes of laser
stimulation - food intake was measured again. Finally, mice were given another 10
minutes post-laser in the testing chamber, and food intake was measured again.

2.2.5.5.

Locomotion and anxiety assays

Four mouse models used for these assays - real time place preference test (RTPP),
open field test (OFT), conditioned place preference test (CPP), and elevated plus maze
(EPM). Either Pdx1-Cre or Vgat-Cre with LH FLEX-ChR2 or LHFLEX-EGFP. Mice were internally
compared with and without laser stimulation, as well as between ChR2 and EGFP groups.
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RTPP: mice were placed into the Noldus behavior chamber and had activity monitored
for 20 min, with laser stimulation paired to one side of the chamber. Testing was initiated
when mouse was in the laser off zone. Half of the mice in each group had the left side of
the chamber paired with laser stimulation, and half with the right side, to counterbalance
possible testing differences. Mouse movement was tracked and analyzed using
EthoVision XT software (version 11.5; Noldus Information Technology, Wageningen,
Netherlands).
OFT:

the periphery of the chamber was determined as ~2 mouse (10 cm) widths; the

patch remaining in the center is the “center.” Mice were tested for baseline levels of
exploration into the center with laser on or off.
CPP:

the center area was paired with laser activation over 7 days. The first day, the laser

was off; then at the same time every day for the next 7 days, mice were exposed to the
laser on-paired with center condition. On the last day, the pairing was extinguished and
mouse preference for the center after 7 days was compared to the first day.
EPM:

mice fasted overnight were then placed on the center of the EPM and habituated

to the apparatus for 10 min. Then, regular chow was placed on either the open or closed
arm. The mouse was then placed on the open arm with the food to allow discovery.
Latency to food consumption was determined as in the feeding behavioral assay; the
mice were allowed 10 min to consume food after first bite.
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2.2.6. Fiber photometry
2.2.6.1.

Equipment

All fiber photometry was conducted using a Doric Lenses setup, with a lightemitting diode (LED) driver controlling two connectorized LEDs (405 and 465 nm) routed
through

a

five-port

Fluorescence

MiniCube

[order

code:

FMC5_AE(405)_AF(420-

450)_E1(460-490)_F1(500-550)_S] to deliver constant illumination of excitation light for
calcium-independent and calcium-dependent signals to the implanted optic fiber
simultaneously. Emitted light was received through the MiniCube and split into two bands
—420 to 450 nm (autofluorescence: calcium-independent signal) and 500 to 550 nm
(GCaMP6 signal: calcium-dependent signal). Each band was collected by a Newport 2151
Visible Femtowatt Photoreceiver module (photometer) with an add-on fiberoptic adapter.
Output analog signal was converted to digital signal through the fiber photometry
console and recorded using the “Analog-In” function on Doric Studios (V4.1.5.2).

2.2.6.2.

Behavioral tests

Looming threat. Mice are acutely sensitive to potential predatory presence and approach,
and this stimulus is anxiogenic i.e. induces behavioral inhibition and potentially a fight-orflight response. While laboratory environment in general has a major influence on mouse
behavior, evidence suggests that experimenters themselves can dramatically increase
rodent stress in ways that seem ethologically indistinguishable from their response to the
presence of actual predators likes cats

348–353

. Given this, rather than work with

complicated mimickers of natural predators for laboratory mice such as a pigeon-sized
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object flying over the cage to mimic a flying predator or an expanding, looming disk

354

,I

used a well-established and simple predatory stimulus to induce anxiety in the animal the looming threat of an experimenter’s hand. Mice were tested in their home cage with
the roof removed; after 3 min of acclimation to the connected cable (recording the entire
time) and while standing over the cage, I placed one hand 2 cage heights above the
mouse for 3 s; and the onset of hand movement was set as time 0. I was the only
experimenter to perform any behavioral assay and responses are only compared prestimulus, during stimulus, and post-stimulus for a given an animal, thus eliminating the
potential influence of inter-experimenter or inter-mouse variation.
Loud sound. Similarly, mice are wary of sudden loud sounds indicating potential danger.
Mice were tested in their home cage with the roof removed; after 3 min of acclimation to
the connected cable, I (positioned across the room out of sight of the mouse and
immobile) clapped hands five times in rapid succession. The onset of clapping was set as
time 0.
Novel object. Mice were placed in a testing chamber and acclimated for 10 min. Then,
recording was initiated; 30 s after recording onset, a novel object (15-ml Falcon tube cap)
was placed in a corner of the cage. The novel object interaction onset was determined by
the moment when the mouse’s nose touched the novel object.
As an aside, I also performed some preliminary tests where the mouse was
exposed to a cotton swab (and later petri dish with a small amount of fluid) soaked in
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commercially available bobcat urine from two different brands, as well as 2phenylethylamine (2-PEA), which is a volatile chemical found in cat urine and is known to
activate the vomeronasal system in mice

355

. However 2-PEA did not induce any sustained

response distinguishable from when I first placed the dish in the cage. Further, from my
subjective perspective, the mice interacted with the swab exactly the same as any other
novel object, generally approaching it within about 5 minutes and showing a short spike
in activity upon interaction with the novel object (see Figure 22) . Although predator urine
has long been used in risk-assessment tests and measures of anxiety with strong circuit
evidence of interaction with the ventromedial hypothalamus

356,357

, it apparently does not

have substantial influence on this system. Alternatively, the laboratory strains of mice that
have been inbred for generations for selection of Cre and flox genes, may have reduction
in sensitivity to these chemicals; knockout of a single trace amine-associated receptor has
been shown to reduce sensitivity to predator odor

358,359

. Finally, there is a possibility that

this may represent fiber implant-related brain damage effects; the midline placement of
the fiber, which must inevitably destroy some midline tissue, could conceivably have
disrupted this sensory pathway

360

. Since I did not pursue this line of experimentation

further, no conclusions can be drawn.
Fasted-refeeding. After a 24-hour fast, mice were placed in a testing chamber and
acclimated for 10 min. Then, recording was initiated; 30 s after recording onset, HFD and
regular chow were placed into two different corners of the testing chamber. Food
consumption bout onset was determined by the moment when the mouse bit the pellet
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(fecal consumption was excluded); food consumption bout offset was set when the
mouse ceased chewing and began investigatory sniffing behaviors/rearing. Two
experimenters (myself and a summer undergraduate researcher, Madhavi Jere)
independently viewed the videos to determine the offset, and the averaged onset/offset
time between the two was used.
Diazepam. Mice were habituated for 2 to 3 min with the cable attached in their home
cage, and then, recording was started. After 2 min, mice were given an intraperitoneal
injection of either saline or diazepam (3 mg/kg; Sigma-Aldrich) and were monitored for
the next 20 min. No food or other stimulus was present during testing.

2.2.6.3.

Data analysis

Fluorescence data were acquired through Doric Studios V4.1.5.2. and saved as
comma-separated files (header was deleted) at a sampling rate of either 1 or 2.5 kS/s. I
wrote a custom analysis script in the R programming language (V3.4.4. “Someone to Lean
On,” packages ggplot2, reshape, zoo, plyr, viridis, and scales) to calculate the baseline
fluorescence (F0) using linear regression across a chosen period of recording. The change
in fluorescence (dF) was then determined from the residuals and multiplied by 100 to
arrive at percentage of dF/F0. A sliding median with a window 51 data points in width was
used to reduce noise. For looming threat, loud sound, and novel object, the baseline was
calculated from 10 s be- fore stimulus onset to 20 s after stimulus onset. For fastedrefeeding, because mice typically engage in a series of quick successive feeding bouts,
the F0 was calculated across a 50-s period with the feeding bout in the center. The
87

average percentage of dF/F0 across the whole period was compared to the average
percentage of dF/F0 during the feeding bout. For diazepam, 1.5 min before
intraperitoneal injection was used to calculate the baseline, and this period was averaged
and compared to a 1.5-min time segment occurring 5 min after intraperitoneal injection.
Stimulation frequency–dependent inhibition. For this test, there was leakage of laseremitted light into the fiber photometer. Two filtering methods were applied: (i) a raw
intensity cutoff slightly higher than the highest natural peak observed in the fluorescence
trace and (ii) a sliding median window 1800 sample points in width (~0.7 s) applied to
eliminate remaining laser-induced artificial light increases.
Fiber photometry heat map. Individual traces were aligned to zero at stimulus onset and
averaged to produce an average trace. These averaged traces were then normalized from
0 to 1 using the R scales package; each mouse’s scaled average trace was combined into a
heat map. The viridis package was used to generate a colorblind-friendly color scheme for
heat map.
NOTE: The calcium-independent fluorescence signal was also recorded during all tests. No
significant alteration in signal level was observed compared to calcium-dependent signal
(indicating steady LED excitation), so I do not display these data for simplicity's sake.

2.2.7. Tissue section imaging and immunohistochemistry
To harvest brain tissue, mice were given a lethal injection of ketamine/ xylazine/
acepromazine. After loss of the pedal reflex, mice were transcardially perfused with 15 ml
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of saline and 15 ml of 10% buffered formalin. The brain was then extracted and stored in
10% buffered formalin for at least 1 day, and then, the brain was switched to 30% sucrose
solution and stored for at least 1 more day. Brains were frozen with dry ice on a
microtome and sectioned into 30 µM slices. The slices were mounted onto microscope
slides and coverslipped with Fluoromount (Diagnostic BioSystems Inc., Sigma-Aldrich). A
confocal microscope was used to image the slices (Leica TCS SP5, Leica Microsystems,
Wetzlar, Germany).
For immunohistochemistry, brains were washed and placed in a blocking solution
for 1 hour (10% donkey serum, 0.3% Triton X-100 dissolved in phosphate- buffered saline),
and then incubated overnight at 4°C with the appropriate primary antibody. Then, after
washing, they were incubated overnight at 4°C with the appropriate secondary antibody.
Purple and green, rather than red and green, were used for ease of visual discrimination.
The following antibodies were used:
Primary:
•

c-Fos rabbit monoclonal antibody (mAb) (9F6) (#2250, Cell Signaling Technology)

•

Orexin A rabbit mAb (#H-003-30, Phoenix Pharmaceuticals)

•

Melanin-concentrating hormone rabbit mAb (#H-070-47, Phoenix Pharmaceuticals)

Secondary:
•

Alexa Fluor 647–conjugated AffiniPure Donkey (H+L) anti- rabbit immunoglobulin G
(Jackson ImmunoResearch)
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Distance from bregma (the intersection of the sagittal and coronal sutures in the
cranium) in millimeters is written next to the scale bar in each image; these are
approximated with reference to Franklin and Paxinos 361.

2.2.8. Statistical analysis
Data were collected into organized Excel (2016) sheets and exported into tabdelimited format. All statistical tests were run using R (V3.4.4. “Someone to Lean On,”
packages ggplot2, reshape, zoo, plyr, viridis, and scales). Mice exposed to two different
conditions were compared using two-tailed paired t test. When two different groups of
mice are tested, they are compared using two-tailed Welch’s unequal variance t test. For
the CNO-blocked feeding test, a one-way ANOVA was used for the three conditions, and
Tukey’s honestly statistical difference (HSD) test was used for post-hoc analysis. Means
and SE are displayed as gray bar graphs behind individual data points. Refer to *** for
analysis of fiber photometry data. Note: in all figures, the following notation is used for
representation of the p value; n.s., not significant. *P < 0.05; **P < 0.01; ***P < 0.001.
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2.3.

Results

2.3.1. LHGABA neurons project to and inhibit DBB neurons to drive feeding
In order to establish the existence of an LH-BF connection, I performed a unilateral
injection of a viral vector encoding FLEX-ChR2-EYFP into the lateral hypothalamus (LH FLEXChR2-EYFP

) of Pdx1-Cre mice. After several weeks to allow full expression, I sacrificed the

mouse to look at the projection targets of these neurons. Previous work in the Tong
laboratory has shown the specificity of this type of injection for the LH

286,294

. LHPdx1-ChR2-EYFP

neurons showed prominent projections to the DBB; implantation of an optic fiber also
successfully targeted those projections in the DBB (Figure 5).
Notably, the dorsomedial hypothalamic nucleus (DMH) is adjacent to the LH and
expresses Pdx1-cre. Thus, it is possible it was also exposed to sufficient level of the viral
vector to also express the fluorescent reporter. Notably, the stereotaxic coordinates and
small volumes of virus used to target the LH generally result in minimal expression in this
region and have been reported in our previous work cited above. Figure 5 shows a
representative image of typical LHPdx1 infection with ChR2. However, some small
contribution of DMH infection cannot be excluded from any of these findings and is a
necessary caveat in the interpretation of the following data.
Photostimulation of those LHPdx1-Chr2-DBBFiber approximated projections resulted in
robust feeding, but photostimulation of LHPdx1-GFP-DBBFiber did not resulted in any feeding,
as seen in Figure 6A. Since LHPdx1 neurons are a mix of GABAergic and glutamatergic
neurons, Dr. Yungang Lu and I used brain slice electrophysiology of postsynaptic DBB
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neurons to determine whether the photostimulation-linked current was excitatory or
inhibitory. Since only optically evoked inhibitory postsynaptic currents (oIPSCs) were
observed, we concluded the LHPDx1-DBB projections were GABAergic, as seen in Figure
6B,C.
I also used two trans-synaptic tracing strategies to further confirm the existence
and molecular identity of the LH→DBB projection. The first strategy used a single-synapse
anterograde virus, AAV1, carrying a plasmid encoding Cre

362

. Injection into the LH of Ai9+

animals revealed Cre activity in the DBB (Figure 7A,B,C) and antibody staining against
choline acetyltransferase revealed that most of the downstream neurons were cholinergic
(Figure 7D-I).
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Figure 5. Optogenetic targeting projections from LH neurons to neurons in the DBB
Coronal brain slices of Pdx1-cre mouse with LH injection of FLEX-ChR2-EYFP (left) and
placement of optic fiber over the DBB (right). Scale bar- 250μM. aca= anterior commissure
anterior limb; DMH = dorsomedial hypothalamus; fx = fornix; HDB = horizontal limb of the
diagonal band of Broca; ic = internal capsule; LH = lateral hypothalamus; mt =

mammillothalamic tract; VMH = ventromedial hypothalamus; VDB = ventral limb of the
diagonal band of Broca; ZI = zona incerta; 3V = third ventricle
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Figure 6. Photostimulation-induced feeding behavior in LHPdx1-ChR2:DBBFiber vs. LHPdx1GFP
:DBBFiber mice and electrophysiological recordings of DBB post-synaptic neurons
receiving monosynaptic input
(A) Activation of LH Pdx1→DBB neurons induces feeding behavior. (B) Brain slice
electrophysiology of downstream neurons in the DBB (n=4 animals) identifies 16 neurons with
inhibitory post-synaptic current (oIPSC), 14 with no response, and 0 with excitatory
postsynaptic current (oEPSC). (C) oIPSC is monosynaptic as it was not blocked by tetrodotoxin
(TTX) + 4-aminopyridine (4-AP). Further, it was also dependent on local GABA-A receptors as it is
blocked by GABAzine (bottom). Photopulse is 2ms. Details for the electrophysiological
experimental setup can be found in Section 2.2.4
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Figure 7. Tracing and identifying DBB neurons that receive direct inputs from LH.
(A-I) Coronal slices of Cre-dependent mCherry+ mouse brain after unilateral injection of
anterograde

tracer

AAV1-Cre-GFP

into

the

LH.

Antibody

staining

against

choline

acetyltransferase (ChAT) is shown. Magenta = mCherry, Green = ChAT. Scale bar- 250μM. Aca =
anterior commissure anterior commissure anterior limb; DMH = dorsomedial hypothalamus;
HDB = horizontal limb of the diagonal band of Broca f = fornix; ic = internal capsule; LH =
lateral hypothalamus; mt = mammillothalamic tract; Nac = nucleus accumbens; opt = optic
tract; VMH = ventromedial hypothalamus; VDB = ventral limb of the diagonal band of Broca;
3V = third ventricle
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Figure 7. Tracing and identifying DBB neurons that receive direct inputs from LH.
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The primary objective of this study was not quantitative analysis of the proportions
of types of each postsynaptic neuron. Thus, I did not pursue further exploration of the
nature of the DBB neurons, having established the monosynaptic connection. This will be
an avenue of study for future researchers.
The second strategy used a retrogradely transported virus, rAAV2-retro, carrying a
plasmid encoding Cre and H2B::Venus
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. Injection into the DBB revealed selective

expression within the DBB and upstream expression within the LH (Figure 8A-C); antibody
staining revealed that these neurons were not substantially colocalized with a melaninconcentrating hormone (Figure 8D-F). As expected, I did identify a subset of presynaptic
neurons in the LH that colocalized with orexin A (the image with greatest colocalization is
presented in Figure 8G-I). Previous research has demonstrated a role for orexin in the
basal forebrain in the sleep/wake cycle

363

. However, given that the only observed

photostimulation-evoked current was inhibitory in the LHPdx1 mice, it is likely that these
neuropeptidergic neurons are not mediating the observed effect. Orexin is usually colocalized with glutamate release machinery, and MCH is typically not colocalized with the
full complement of either GABA or glutamate release machinery 364,365.
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Figure 8. Tracing LH neurons that send direct projections to DBB neurons.
(A-C) Coronal slices of mouse brain after midline injection of retrograde tracer rAAV2retro carrying a plasmid encoding Cre and H2B::Venus (green) into the DBB, demonstrating
selective expression in the MS/DBB and its presynaptic targets. (D-F) Antibody staining against
orexin (purple) demonstrates minimal colocalization. (G-I) Antibody staining against melaninconcentrating hormone (MCH; purple) demonstrates no colocalization. Scale bar- 250μM. aca
= anterior commissure anterior limb; AHP = anterior hypothalamic area, posterior part; BMA =
basomedial amygdala; CeA = central nucleus of the amygdala; DMH = dorsomedial
hypothalamus; HDB = horizontal limb of the diagonal band of Broca f = fornix; ic = internal
capsule; LH = lateral hypothalamus; LS = lateral septum; MS = medial septum; mt =
mammillothalamic tract; meAD = medial amygdaloid nucleus; Nac = nucleus accumbens; opt =
optic tract; VMH = ventromedial hypothalamus; VDB = ventral limb of the diagonal band of
Broca; 3V = third ventricle

98

Figure 8. Tracing LH neurons that send direct projections to DBB neurons.
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My data on feeding and predominant oIPSCs recorded from photostimulated
LHPdx1-Cre neuron projections suggest a potential dominance of GABAergic projections
in the LH→DBB pathway. Thus, I used vesicular GABA transporter (Vgat)-cre mice
selectively target LHGABA neurons (LHVgat or LHGABA) for optogenetic
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to

manipulations.

Targeting LHVgat neurons with AAV-FLEX-ChR2 (LHVgat-ChR2) revealed dense fibers in the DBB,
as can be seen in the top row of Figure 9. Figure 9A shows the generalized virus injection
strategy. Labeling LHVgat neurons with Synaptophysin::EGFP revealed specific GABAergic
synaptic terminals in the DBB, as can be seen in the bottom row of Figure 9.
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Figure 9. LHVGAT-ChR2 and LHVgat-Synaptophysin::GFP neurons project to and synapse in the DBB
(Top row) (A) Diagram demonstrating LH injection with AAV-FLEX-ChR2-EYFP and
implantation of optic fiber over the DBB. (B) Representative coronal slices of LHVgat-ChR2-EYFP
(left) and EYFP+ fibers in the DBB (right). (Bottom Row) Injection of LH Vgat neurons with FLEXSynaptophysin::EGFP reveals strong synaptic projection to the MS and VDB/HDB, with only
sparse connection LS or NAc/NAcSh. Scale bar- 250μM. aca = anterior commissure anterior
limb; Arc = arcuate nucleus of the hypothalamus; fx = fornix; ic = internal capsule; iCj = islet of
Cajal; LH = lateral hypothalamus; LS = lateral septum; MS = medial septum; mt =
mammillothalamic tract; NAc = nucleus accumbens; NAcSh = nucleus accumbens shell; opt =
optic tract; VMH = ventromedial hypothalamus; VDB = ventral limb of the diagonal band of
Broca; 3V = third ventricle
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Figure 9. LHVGAT-ChR2 and LHVgat-Synaptophysin::GFP neurons project to and synapse in the DBB
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Activation of LHVgat-ChR2→DBB projections induced rapid, light-locked feeding
behavior, recapitulating our findings with LH Pdx1-ChR2 mice (Figure 10A). LHVgat-ChR2 lightinduced feeding was prevented by per-microinjection of GABAzine, a GABA-A receptor
antagonist, to the DBB (Figure 10B). From these data, we conclude that the LH GABA-DBB
neurocircuit promotes feeding. Further, the local injection of GABAzine demonstrates that
the feeding effect that we observed is not due to back-propagation of action potentials to
LHVgat somata or axon collaterals to other regions.
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Figure 10. Activation of LHVGAT-ChR2-DBB projections induces feeding blockable by local
GABAzine
(A) Food intake of fed mice during 10-min periods before (pre), during (stim),and after
(post) photostimulation of LHGABA→DBB projections (n = 15, P < 0.001). (B) Effect of DBB
pretreatment with GABAzine (ɣ-aminobutyric acid type A (GABA-A) receptor antagonist) or
saline on photostimulation-induced feeding (n=5, P=0.015).
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2.3.2. LHGABA-DBB activation alters preference for palatable foods
Since feeding behavior is influenced by food palatability, we next explored whether
the observed feeding was dependent on the evaluated palatability of the food to be
consumed. This is particularly interesting given that activation of somatostatin-positive
neurons (likely also GABAergic) in the basal forebrain selectively induced consumption of
a palatable food for rodents, high-fat diet (HFD)

. In my experiments, as expected,

366

control mice in the fasted (12 hours) state selectively consumed HFD instead of standard
chow (Figure 11A). However, LHGABA→DBB activation in the fed state elicited indiscriminate
consumption of both chow and HFD (Figure 11B). This indicates an alteration in the
evaluation of the palatability of the food; or, put another way, either appetite is increased
such that the value of the foods cannot be distinguished as they both become highly
palatable, or the standard chow’s palatability was increased. To test the extent of altered
food palatability caused by circuit activation, we next created a competition paradigm,
where fasted mice must choose between chow paired with photostimulation and
unpaired HFD; they uniformly preferred stimulation-paired chow (Figure 11C,D)
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Figure 11. Activation of LHGABA-DBB projections drives indiscriminate feeding
(A-B) Mouse preference for high-fat diet (HFD) or chow in the fasted state (E; n = 6, P =
0.019) and in the fed state with photostimulation (F; n = 9, P = 0.96). (C) Representative trace of
a single mouse’s movement during competitive choice test. Regular chow (reg) is paired with
photostimulation. (D) photostimulation-paired chow consumption compared to nonpaired HFD
consumption (n=5, P= 0.011).
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Last, to test whether circuit activation is merely magnifying hunger or having other
effects with positive valence, we extended the competition paradigm to force mice to
choose either photostimulation or chow consumption over 10 min. The pairing was then
removed, and food consumption over the next 10 min was measured to determine
whether mice retained hunger after ceasing stimulation. As expected, in the control
condition, mice approached food right away and ate food during both 10-min epochs
(Figure 12A). However, when forced to choose between photostimulation and food, mice
refrained from eating until stimulation was removed (Figure 12B,C). Prolonged fasting (24
hours) reduced this preference (Figure 12D), suggesting that activation is not sufficient to
overcome intense physiologic hunger induced by 24-hour fasting.
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Figure 12. Activation of LHGABA-DBB projections is preferable to feeding, except in
extreme hunger.
(A) Food consumption in 10-min increments upon food exposure after 12-hour fasting
(n = 6, P = 0.028). (J) Representative trace of mouse movement when choosing between
photostimulation or chow consumption after 12 hours (hrs) of fasting. (K and L) Food
consumption when choosing between chow and photostimulation after 12 hours during the
photostimulation period (0 to 10 min) and after photostimulation is ended (10 to 20 min) (K; n
= 6, P = 0.001) and 24-hour fasting (L; n = 9, P = 0.34).
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2.3.3. LHGABA-DBB activation reduces anxiety
Given the results of the competition experiments, I next examined how circuit
activation affects behavior in the absence of food altogether. First, I established that
activation has a positive valence using the real-time place preference (RTPP) test. In the
RTPP test, mice are allowed to move freely between sides of the chamber, with one side
paired

with

photostimulation.

LHVgat-ChR2

mice

preferred

the

area

coupled

to

photostimulation, whereas LHVgat-GFP had no preference (Figure 13A,B). Notably, there was
no difference in locomotion within the paired area (Figure 13C). I next tested mouse
behavior on the open-field test (OFT), where the entire chamber is paired with
photostimulation (Figure 13D); in this case, mice spent more time in the center and
moved more in the OFT (Figure 13E,F).
It is interesting that in this particular test, there appeared to be bimodality to the
response - this was not attributable to sex or litter, as far as I could discern. On the
recorded video of mouse behavior, my subjective observation is that in the latter half of
the test it becomes clear that the mice generally sit and 'stay put' in a randomly chosen
location - sometimes that is within the designated center, and sometimes that is not. This
may contribute to some extent of the disparity seen. Interestingly, food availability seems
to reduce the observed increase in locomotion (likely because they are eating). This may
also explain why the example movement trace in the absence (Figure 13A) of food covers
greater area than in the presence (Figure 11C) of food.
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It is important to note that the OFT, as used in this section, does not differentiate
between a total increase in locomotion then leading to an increase in center time, versus
a preferential increase in resting time in the center – a problem that has long been
appreciated, but is often under-discussed, as a limitation to interpretations of the OFT
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.

The ratio of locomotion to percent time spent in the center is difficult to interpret,
because as described above, the mouse’ movement across time is not uniform and there
may be artifacts of either latency to initiate moving, or the converse early fatigue leading
to lack of future exploration. For example, a study using detailed manual ethological
analysis of mice under the influence of diazepam and chlordiazepoxide versus a pulsed
low frequency magnetic field found distinguishable effects between agents, despite all
increasing center time 377. Future tests may be done where movement across time is
separated into small chunks (e.g. 1 minute intervals), and the amount of locomotion per
minute and percent center time can be shown as a trend. However, in each of the cases
above, an increase amount of time spent in the center is still a proxy for relative
behavioral disinhibiton (i.e. reduced anxiety)
conclusion that

increased

percent

time
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. For the purposes of this experiment, the

spent

in

the

center

reflects

relative

disinhibition/reduced anxiety is sufficient. Later experiments tackle anxiety/disinhibiton
through other means.
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Figure 13. Mice prefer activation of the LHGABA-DBB neurons and have reduced anxiety
(A to C) Effect of photostimulation of LHGABA→DBB projections on RTPP test (n = 14 per
group). (A) Representative trace of mouse movement

(black) in gray zone and

photostimulation-paired magenta zone (stim zone). (B and C) Comparison between LHVgatChR2 mice and LHVgat-GFP mice on percentage of testing time spent in stim zone (B; P < 0.001)
and average velocity in stim zone (C; P = 0.15). GFP, green fluorescent protein. (D to F) Tenminute OFT in LHVgat-ChR2 mice (n = 9): Photostimulation effect on mouse movement (black
trace) on OFT (D; center is shaded gray) and effect of photostimulation on percentage of time
in center (E; P = 0.015) and distance traversed (F; P = 0.038).
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To test the extent of positive valence encoded by photostimulation, I tested
whether mice were willing to overcome the inherent anxiety of being in the center to
receive photostimulation. They demonstrated preference for the center when it was
paired with stimulation (Figure 14). However, this preference was quickly lost once
photostimulation was removed, even after 7 days of training on the conditioned place
preference (CPP) test. (Figure 14). These results suggest that the positive valence effect of
circuit activation may be primarily related to its alleviation of anxiety, rather than
independently rewarding.
Given the two major behavioral phenotypes observed—reduction in anxiety and
increase in hunger—I next sought to examine the causal relationship between these two
behaviors. First, we examined whether stimulation results in a greater amount of food
consumed per minute or a faster food approach (i.e., reduced latency to onset of
feeding). Notably, shorter latency to food consumption is a classic marker of reduced
anxiety and is a standard metric used to judge the efficacy of anti-anxiety medication
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found that photostimulation of fed mice reduced latency to onset of feeding as compared
to mice that fasted for 24 hours (Figure 15A). However, it does not seem to indicate a
substantial increase in hunger, as the total amount of food consumed was comparable
and there was no difference in the feeding rate from onset of consumption to end of test
(Figure 15B,C).
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Figure 14. Activation of LHVgat-ChR2-DBB projections only induces transient center
preference
(A-B) CPP test for photostimulation-paired center in LHVgat-ChR2 mice over 20 min per
test (n = 9): mouse movement in chamber with (magenta) or without (gray) photostimulationpaired center (G), and effects of training on percentage of time spent in center initially without
stimulation compared to the first training day (P = 0.007) and last training day to nophotostimulation extinction phase (24 hours after day 7; P < 0.001)
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Figure 15. Activation of the circuit reduces anxiety so as to allow food consumption
to occur
(A-C) Effect of photostimulation of LHGABA→DBB projections on feeding behaviors
compared to 24-hour fasted mice (n = 15 per group): Effect of photostimulation on latency to
feeding (A; P < 0.001) and food consumed (B; P = 0.022). (C) Food consumed per minute of
feeding (P = 0.09).
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To further examine the interaction between anxiety and hunger, I explored how
placement of HFD on the open or closed arm of an elevated plus maze (EPM) with regular
chow on the converse arm affected consumption after fasting (Figure 16). It is well
established that being on the open arm is aversive to rodents and that they strongly
prefer the closed arm. My earlier data (Figure 11) indicate that mice naturally prefer HFD
over chow when given equal access. Coincident with this, when HFD is located on the
closed arm, fasted mice began eating HFD immediately and never touched the chow.
However, in the flipped condition, there was increased latency to HFD approach, reduced
HFD consumption, decreased latency to chow approach, and increased chow
consumption.
Given that placing palatable food on the open arm reduced its value, I next
isolated the effect of food placement on feeding behavior (Figure 17A). Fasted mice
showed reduced latency and increased consumption when food was placed on the closed
arm as opposed to the open arm (Figure 17B,C). Last, activation of the LH GABA→DBB
neurocircuit markedly reduced the latency to feeding on the open arm while producing a
comparable amount of food consumption (Figure 17D,E). From these results, I concluded
that (i) anxiety imposed by environment substantially affects both feeding behavior and
food choice and (ii) LHGABA→DBB activation reduces this environmental anxiety to allow
feeding to occur.
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Figure 16. Competition between anxiogenic conditions and feeding behavior.
(A-F) Mice (n=20) were fasted overnight prior to all experiments and habituated to the
elevated plus maze (EPM) prior to food placement; lines connect same mouse across
conditions. (A-B) Schematic representing two experimental conditions: condition 1, regular
chow (reg) is placed on the open arm of the EPM and high fat diet (HFD) on the closed arm;
condition 2, regular chow is placed on closed arm and HFD on the open arm (C) Latency to
regular chow consumption between the two conditions(p<0.001) (D) Amount of regular chow
consumed for 10 minutes after first bite (p<0.001) (E) Latency to HFD consumption between the
two conditions (p<0.001) (F) Amount of HFD consumed for 10 minutes after first bite (p<0.001).
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Figure 17. Activating the LHGABA-DBB circuit reduces environmentally-driven anxiety
to allow feeding
(A-E) Influence of food location on open or closed arm of EPM on fasted-refeeding
response in control mice (n = 20). (A) Schematic showing two testing conditions: food placed on
the closed (gray) arm or food placed on the open (white) arm. (B) Latency to the first bite of
food in closed or open condition (P < 0.001). (C) Consumption 10 min following first bite (P <

0.001). (D-E) Influence of activation of L HGABA→DBB on feeding when food was on open arm of
EPM (n = 7). (D) Latency to the first bite of food on open arm when fasted or fed and with
(+stim) laser stimulation (P = 0.004). (E) Consumption 10 min following the first bite (P = 0.06).
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2.3.4. LHGABA neurons specifically target DBBGABA neurons
Having established the behavioral consequences of circuit activation,

I next

explored what types of neurons within the DBB are postsynaptic to LH GABA→DBB
projections. The DBB contains both glutamatergic and GABAergic neurons; the latter
includes acetylcholine and somatostatin co-releasing neurons

370–372

. First, I used a double-

injection method of ChR2 into the LH and a Cre-dependent fluorescent label in the DBB
of Vgat-cre or Vglut2-cre mice and then Dr. Yungang Lu performed brain slice
electrophysiology (Figure 18A). In Vgat-cre, I targeted the LH with AAV-FLEX-ChR2-EYFP
and the DBB with AAV-DIO-hM3Dq-mCherry (marking LH Vgat fibers with EYFP and DBB Vgat
neurons with mCherry). In Vglut2-cre, I targeted the LH with AAV-Fas-ChR2-mCherry and
the DBB with AAV-FLEX-EGFP. The Fas-ChR2 vector is “Cre-Off,” such that only neurons that
do not express Cre will express ChR2 . This means that LH Non-Vglut2 fibers will be marked
with mCherry and that DBBVglut2 somata will be marked with enhanced green fluorescent
protein (EGFP). Patching the fluorescent cell bodies in the DBB allowed molecular
identification of the downstream target. From all neurons recorded, only DBB GABA neurons
were shown to receive inhibitory input (Figure 18B,C).
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Figure 18. Electrophysiological recordings in the DBB reveals an LHGABA-DBBGABA
circuit
(A to C) DBBGABA neurons receive direct synaptic input from LH GABA neurons. (A) Schematic
showing Vgat-cre mice receiving LH injection of AAV-FLEX-ChR2 (LH Vgat-ChR2) and DBB injection of
AAV-DIO-hM3Dq-mCherry (DBBVgat-hM3Dq), and Vglut2-cre mice receiving LHVglut2-Fas-ChR2:DBBVglut2hM3Dq

. (B-C) Brain slice electrophysiology of oIPSC in DBBmCherry+ and DBBmCherry− neurons of LH Vgat-

ChR2

:DBBVgat-hM3Dq-mCherry mice (B; n = 3) and LHVglut2-Fas-ChR2:DBBVglut2-hM3Dq-mCherry mice (C; n = 2).

119

I next sought to validate these data in vivo using a similar targeting strategy
(Figure 19A). Vgat-cre mice received an injection of AAV-FLEX-ChR2 into the LH, and AAVFLEX-DIO-hM3Dq-mCherry. NOTE: hM3Dq is a a synthetic excitatory receptor that can be
activated with clozapine-N-oxide (CNO); see Figure 20 top for fluorescent pattern and CNOinduced c-fos expression. Pretreatment of LHVgat-ChR2: DBBVgat-hM3Dq mice with CNO
substantially reduced the amount of photostimulation-induced feeding (Figure 19B). I
also used the converse strategy, where Vglut2-cre mice received an injection of AAV-FasChR2 in the LH and AAV-FLEX-hM3Dq-mCherry in the DBB (Figure 20 bottom).
Pretreatment of LHVglut2:Fas-ChR2:DBBVglut2-hM3Dq mice with CNO had no effect on stimulationinduced feeding (Figure 19C).
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Figure 19. Preactivation of DBBVgat, but not DBBVglut2, neurons prevents stimulationinduced feeding
(A) Schematic demonstrating targeting strategy. (B and C) Effect of CNO-mediated
activation of DBBhM3Dq on photostimulation-induced feeding in LHVgat-ChR2:DBBVgat-hm3Dq mice [oneway analysis of variance (ANOVA) and Tukey post hoc test] (B; n = 11; saline:photostimulation,
P < 0.001; saline:CNO-photostimulation, P = 0.07:photostimulation:CNO-photostimulation, P <
0.001), and LHVglut2-Fas-ChR2:DBBVglut2-hm3Dq mice) (C; n = 8; saline:photostimulation, P = 0.002;
saline:CNO-photostimulation, P = 0.006; photostimulation:CNO-photostimulation, P = 0.88).
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Figure 20. Administration of CNO induces c-Fos in DBBVgat and DBBVglut2 neurons
(Top Row; scale bar = 250μm) Brain slices showing expression DIO-hm3Dq in DBB Vgat neurons
(magenta); c-fos immunohistochemical staining (green) in these neurons 3 hours after injection
of clozapine-N-oxide (CNO). (Bottom Row; scale bar = 100μm) Brain slices showing expression
of DIO-hm3Dq DBB Vglut2 neurons (magenta) and c-fos expression (green) 3 hours after
injection of CNO. Red Arrows indicate co-localization. HDB = horizontal limb of the diagonal
band of Broca; LSv = lateral septum ventral part; MS = medial septum; NAc = nucleus
accumbens; NAcSh = nucleus accumbens shell; VDB = ventral limb of the DBB
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To further confirm the LHGABA→DBBGABA connection, I used real-time fiber
photometry of calcium-dependent fluorescence from LH GABA and DBBGABA neurons
expressing AAV-DIO-GCaMP6m

335

. This allows the identification of changes in neuronal

population activity at the sub-second level (this particular protein easily allows
determination of differences across 100ms). First, I sought to determine how these two
populations of neurons respond to feeding. After fasting, simultaneous recording of
LHVgat-GCaMP6m and DBBVgat-GCaMP6m neurons showed that, as LHGABA neurons increased their
activity (Figure 21A top), DBBVgat neurons showed a concomitant decrease (Figure 21A
bottom) specifically during the feeding bout.
Last, I sought to demonstrate in vivo that activation of LH Vgat-ChR2 neurons produces
a time-locked reduction in activity of DBBVgat neurons. Simultaneous photostimulation of
LHVgat-ChR2 cell bodies and fiber photometry recording from DBB Vgat-GCaMP6m cell bodies
demonstrated both a pulse frequency–dependent and a pulse duration–dependent
reduction in DBB fluorescence (Figure 21B,C). Together, these results convinced us that
LHGABA neurons specifically inhibit DBBGABA neurons in real time, with the strength of LH GABA
activation producing greater amounts of DBBGABA inhibition.
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Figure 21. Fiber photometry of LHVgat and DBBVgat neurons reveals inverse activity
relationship
(A) Simultaneous recording of LHVgat-GCaMP6m and DBBVgat-GCaMP6m population activity during
feeding bouts (shaded areas) recorded after 12hrs of fasting and free access to food. (B,C)
Effect of photostimulation of LHVgat-ChR2 cell bodies on DBBVgat-GCaMP6 neuronal activity at various
frequencies (B) and pulse durations (C).
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2.3.5. DBBGABA neurons are highly sensitive to anxiogenic environmental cues
Having demonstrated the specific connection between LHGABA and DBBGABA neurons,
I then sought to look at the conditions in which DBB GABA neurons are activated. I
monitored activities of DBBVgat-GCaMp6m neurons (Figure 22A,B) in several conditions. I
observed that voluntary interaction with a novel object correlated with increased DBB VgatGCaMP6m

activity during the period of active investigation of the novel object; this was

repeatable across interactions and between mice (Figure 22C picture inset demonstrating
what was coded as stimulus onset). In addition, both looming threat (Figure 22D) and
loud sound (Figure 22E) stimuli increased DBBVgat-GCaMP6m activity. Each of these is a sign of
danger for a laboratory mouse

348–353

and indicates that these neurons are involved with

heightened attention to anxiogenic stimuli.
Conversely, DBBVgat-GCaMP6m neurons showed decreased activity during feeding
bouts, consistent across feeding bouts and between mice (Figure 23A,B). Last, treatment
with diazepam, an anti-anxiety benzodiazepine known to reduce latency to food
consumption

, reduced DBBVgat-GCaMP6m activity (Figure 23C,D). Administering diazepam

369

to fed mice caused feeding (Figure 23E). Further, administration to fasted mice caused
indiscriminate feeding when given access to both chow and HFD simultaneously (Figure
23F). From these data, I concluded that DBB GABA neurons respond to environmental cues
of threat and reduce their activity during feeding.

I also concluded that diazepam

reduced DBBGABA neuronal activity and recapitulated the indiscriminate feeding phenotype
produced by LHGABA→DBBGABA activation.
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Figure 22. Multi-modal anxiogenic stimuli cause an increase in DBBVgat activity
(A to E) Response of DBBVgat-GCaMP6m neuronal population to threatening
environmental stimuli. (A) Schematic of DBBVgat-GCaMP6m injection and optic fiber placement
strategy. (B) Brain slice with DBBVgat-GCaMp6m neurons (VDB); arrows indicate cell bodies.
MS, medial septum. (C to E) DBBVgat-GCaMP6m neuronal activity change in response to
stimulus (onset at 0 s) with gray traces indicating single interactions, magenta traces
indicating averaged response, and heat map indicating normalized average responses per
mouse in response to novel object interaction (C; inset shows stimulus onset), looming threat
(D), & loud sound (E). MS = medial septum; NAc = nucleus accumbens; VDB = ventral limb of
the DBB
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Figure 23. Feeding bouts cause a reduction in DBBVgat activity and diazepam
recapitulates the effects of activating the LHGABA-DBBGABA circuit.
(A,B) Response of DBB Vgat-GCaMP6m neurons to feeding in the fasted condition with
representative trace during feeding bouts (A; shaded gray) and averaged activity during
feeding bout compared to average activity over relevant testing period (B; n = 5, P = 0.002). (C
to D) Effect of diazepam (DZP) on DBBVgat-GCaMp6 neuronal activity and feeding behavior. (C) Effect
of intraperitoneal DZP on DBB Vgat-GCaMp6m neuronal activity in comparison with intraperitoneal
saline; (D; n = 4, P = 0.002) Averaged activity min before injection compared to average activity
3 to min after injection. (E) Effect of intraperitoneal injection of saline versus DZP on feeding (n
= 15) when fed (P < 0.001). (F) Effect of DZP on fasting-induced food intake of chow and HFD
when presented with free access to both simultaneously for 2 hours (chow, P = 0.001; HFD, P =
0.421).
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2.4.

Conclusions and significance
In this study, I found a previously unidentified LH GABA→DBBGABA pathway that

promotes feeding by suppressing environmentally driven anxiety. This projection likely
acts in concert with other known projections of LH GABA neurons to coordinate successful
feeding 286,294–296,298,302. In vivo fiber photometry data show that DBB GABA neurons respond to
anxiogenic environmental stimuli and reduce activity during feeding. This is consistent
with the known function of DBB neurons in promoting environment-responsive arousal
. My data thus suggest that LH GABA neurons not only induce appetitive and

312,315,366,373,374

consummatory behaviors but also alter sensitivity to the environment to promote feeding
behavior.
Since the induced feeding state observed here is indiscriminate, this suggests that
some of the altered sensitivity may result via altered evaluation of food value itself. This
aligns with the converse phenotype of picky eaters who have anxious personalities and
with a study showing that activation of forebrain somatostatin neurons increases anxiety
with selective consumption of a calorie-dense diet

. I further explored this point and

372,375

demonstrated that environmentally driven anxiety is a key mediator in the selection and
proportion of low-value, but safe food consumed compared to high-calorie, but unsafe
food. Moreover, the recapitulation of my circuit data with the effects of diazepam further
points to the fundamental link between anxiety, food evaluation, and food consumption.
Notably, despite verifying LH targeting for included mice, because of inherent
variation associated with stereotaxic injections and the continuous distribution of
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GABAergic and PDX1 neurons between the LH and nearby regions, e.g., the dorsomedial
hypothalamus, I could not completely rule out a slight contribution of nearby non-LH GABA
neurons in some mice tested in our study. Thus, it is possible that the DMH also plays a
role in the findings discussed in these results.
From a pharmacologic perspective, my data are notable because one of the most
troubling aspects of nearly all psychotropic agents for anxiety and depression is their
strong tendency to induce hunger, weight gain, and metabolic disease

270

. These include

drugs used for children with sensory processing disorders, such as risperidone for autism
376

. Further, given recent compelling data demonstrating that LH GABA neurons can be

activated by the mere presence of and consumption of rewarding foods and encode
reward prediction regardless of hunger

296

, it is conceivable that the LH GABA→DBBGABA

neurocircuit may be involved in “stress eating,” i.e., consumption of foods in the nonhunger state in order to reduce feelings of anxiety. A clinical example of this may be the
compulsion to binge seen in binge-eating disorder after acute stress

131,269

. Mechanistic

demonstration of the direct link between the hedonic LH and the anxiogenic DBB
provides tantalizing evidence that this heretofore difficult-to-define behavior in humans
may have firm grounding in neurobiology. Knowledge of the neurocircuitry mediating the
tight connection between hunger and anxiety provides a mechanistic platform for specific
development of behavioral interventions and therapeutics against eating and anxietyrelated disorders.
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Chapter 3. Real-time monitoring of the paraventricular hypothalamic nucleus
and ventral lateral septum reveals tight inverse association between anxiety,
stress-responses, and eating.
This chapter is based upon: Xu YZ*, Lu Y*, Cassidy RM*, Mangieri LR, Zhu C,
Huang X, Jiang Z, Justice NJ, Xu Y, Arenkiel BR, Tong Q. Identification of a
neurocircuit underlying regulation of feeding by stress-related emotional
responses. Nature Communications 2019 10:3446 *Co-first authors
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3.1.

Rationale
In addition to the LH-DBB circuit discussed in Chapter 2, there are obviously many

other neurocircuits that respond to hunger and anxiety that have neurodynamics
reflecting the competition between these two affective states. More broadly in cognition
and memory, these can be described as brain states. The septohippocampal connections
have long been known to, once reaching a threshold of activity, induce fight-or-flight
behavior or what may be called panic

377–379

learning or avoiding dangerous stimuli

. The destruction of the septal nuclei prevents

380,381

. Further, it appears that the interaction

between the BF and the septal nuclei may drive the presence of the rhythmic firing
activity observed on electroencephalography (EEG) over the cortex and hippocampus
associated with distinct arousal and attentional brain states: low synchronized firing rates
produce theta and delta rhythms associated with memory recall, feeding, and passive
observation, whereas high frequency firing rates produce gamma and alpha rhythms
associated with attention 311,366,374,380,382,383. Thus, much work conducted on the septal nuclei
has focused on its role in entraining these observed EEG rhythms and establishing the
role of these rhythms in producing the above observed brain states. The influence of the
hypothalamus on this region in mediating the switching from one brain state to another
has not been well-established.
However, as with the LH-DBB circuit, our lab possessed data indicating that
hypothalamic nuclei also send projections to this region. Given our concurrent work
showing the role of activation of PVH glutamatergic (PVH glut) neurons in preventing
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feeding and inducing self-grooming and defensive behaviors by their projection to
glutamatergic neurons in the

VTA 281,282

, and the parallel LH inhibitory circuit from the LH-

DBB, we decided to use a similar set of techniques as used in Chapter 3 to establish the
role of the putative PVH-LSv circuit in mediating hunger, anxiety, and fight-or-flight
responses.
Because of the complexity of these tools (particularly electrophysiology, behavioral
assays, and fiber photometry data acquisition and analysis) and the relative levels of
expertise possessed by each member, the three co-first authors of this paper contributed
their expertise to generate and analyze data about this circuit’s function at the
electrophysiological (Yungang Lu), behavioral (Yuanzhong Xu), and real-time neural
activity monitoring (myself) levels. In section 3.2, I have only introduced the methods
relevant to the data discussed in detail in section 3.3. To provide context for this data, I
have provided a brief summary of the findings produced by Drs. Xu and Lu at the
beginning of section 3.3 before discussing in detail the results of the fiber photometry
experimentation. NOTE: Dr. Xu performed the surgeries, brain slicing, and the behavioral
experiments. We jointly developed the behavioral testing paradigms. I set up the equipment,
wrote in-house code, analyzed the data sets, and produced all of the graphs.
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3.2.

Material and Methods

NOTE: Only those methods that differ from section 2.2 and which were involved in
generating the data discussed in this section have been presented here.
Animal Models
The following transgenic Cre mouse line was used: Sim1-Cre (Single-minded 1

384

,

known to be expressed primarily within the PVH in a fashion similar to Pdx1-Cre).
The following knock-in mouse lines were used: vglut2 flox (to create the glutamate
release knockout model, Sim1Vglut2 F/F,) 292,384 and Vgat-Cre.
In vivo fiber photometry experiments: Sim1-Cre mice with specific delivery of AAV-FLEXGCaMP6m to the PVH and optic fiber implantation targeting PVH neurons and Vgat-Cre
mice with specific delivery of AAV-FLEX-GCaMP6m to the LSv and optic fiber implantation
targeting LSv were used for the in vivo fiber photometry Ca2+ imaging studies. In
retrograde studies, rAAV2-retro-EF1a-Cre-Venus viruses were injected to the LSv of wildtype mice and the AAV-FLEX-GCaMP6m viruses were injected to the PVH. The recording
was performed 6 weeks after the surgery. The GCaMP6m virus was provided by the
Baylor NeuroConnectivity Core. The experiments were conducted at least 4 weeks after
the surgery. We used the fiber photometry system from Doric Lenses to monitor Ca2+
signal from a group of PVH Sim1 neurons and LSv GABAergic neurons. Mice were
acclimated to the behavioral chamber for at least 15 min prior to the beginning of each
testing session. After baseline recording for 10 seconds, water spray was started by
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spraying one time with water toward the head of mice with a sprayer and the recording
continued for ~ 2 mins. For feeding studies, fasted or well-fed mice were acclimated in the
cage for at least 5 mins before one high-fat diet pellet was introduced to the cage. Mouse
behaviors including feeding were videotaped simultaneously with photometry recording.
Data were acquired and analyzed in the same manner as in section 2.2.6. For water
spray, loud sound, and light, the baseline was calculated from 10 seconds prior to
stimulus onset, to 20 seconds after stimulus onset. Note that water spray consisted of
two quick puffs into the face, light was an immediate switch from dark to light, and loud
sound is as is described in section 2.2.6.
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3.3.

Results

3.3.1. Summary of findings collected by Dr. Xu and Dr. Lu on the description
and function of the PVH-LSv circuit.
Through the work of Dr. Xu and Dr. Lu, our laboratory demonstrated the following
key pieces of information about the PVH-LSv connection using Sim1-cre mice:
1. The PVH-LSv neurocircuit is glutamatergic and prevents feeding behavior by
inducing aversion, anxiety, and the flight response. This connection is
monosynaptic onto GABAergic neurons within the LSv. Microinjection of a
glutamate receptor antagonist (DNQX+AP5) into the LSv increased the amount of
time spent on the exposed arm of the EPM as well as induced feeding behavior.
2. Photostimulation of the PVH-LSv circuit induces self-grooming and escape
behavior, best described as sprinting to the edge of the cage and jumping, or
hiding in a hut. Further, it appears that the intensity of the signal is the primary
determinant as to whether a mouse self-grooms or escapes, as the same mouse
with low laser pulse duration grooms and at high pulse-duration jumps (though
for some mice this was not scalable). Mice will also work to avoid laser stimulation
on the RTPP and OFT. Conditioned place avoidance was not tested. Finally, circuit
activation interrupts aggressive attacks during the resident-intruder assay in
males, where the mouse with an optic fiber implant is exposed to an intruder in
the home cage - something that normally induces attack.
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3. Photostimulation of the PVH-LSv circuit prevents fasted mouse feeding; however,
the inhibitory effect is reduced and eventually abolished as the mouse becomes
progressively hungrier (6hrs fasting vs 12hr vs 20hr). Increased pulse durations
still caused a reduced amount of eating for a given degree if hunger. At 6hrs
fasting, mice consumed no food over 15 minutes; in 20hr fasting, there was an
average 0.1g reduction in food consumption in the long pulse duration condition
compared to short pulse duration (average ~0.2g total) over 15 minutes.

3.3.2. PVH and LSv neurons are sensitive to environmental stressors
In light of the above information, we next sought to explore the normal ethology
of both PVH and LSv neuronal activity as related to feeding behavior and environmental
anxiogenic cues, as established in my work on the LH-BF neurocircuit (section 2.3.5). To
examine the function of the PVH-LSv projection in sensing environmental cues, we
targeted PVH and LSv neurons for GCaMP6m expression and monitored their activity
using fiber photometry. Three experimental setups were used:
3.3.2A PVH cell bodies were recorded after PVHSim1 injection of GCaMP6m (PVHSim-GCaMP6)
3.3.2B LSv cell bodies were recorded after LSvVgat injection of GCaMP6m (LsvVgat-GCaMp6).
3.3.2C PVH cell bodies were recorded after LSv injection of retrograde AAV capsid bearing
Cre (c.f. section 2.3.1), with simultaneous PVHLSv-targeting

injection of GCaMP6m

(PVHLSV-retro-GCaMp6). This allowed recording from neurons that send projections to
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the LSv. These injection strategies and the placement of fibers can be seen in Figure 24AD.
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Figure 24. Targeting of GCaMP6m into the PVH and LSv for recording of real-time
neural activity.
NOTE: Images taken from Dr. Yuanzhong Xu with permission. (A-D) Expression of
Campagna and fiber photometer tract for recording of activity (A) Expression of GCaMP6 in
PVHSim1 neurons (B) Expression of GCaMP6 in LSV Vgat neurons (C) Expression of retroAAV-Cre in
the LSv of a Cre-negative mouse (D) Expression of Cre-dependent GCaMP6 in the PVH of the

mouse infected with LSV retro-Cre. Scale bar = 100µM. AcbSh = accumbal shell; LSv = ventral
lateral septum; 3V and LV = third and lateral ventricle. PVH = paraventricular hypothalamic
nucleus.
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Next, as in section 2.3.5 we monitored the activity of each of these regions during
multiple ethologically relevant conditions. First, we examined the relative activity of the
PVH and the LSv during fasted-refeeding. As seen in Figure 25, the PVH and LSv neurons
both, over repeated trials, show an immediate and sustained drop in population-level
activity during the feeding period. The reduction in activity stops as soon as the feeding
bout has ceased. This is similar to the feeding-induced suppression of the DBB seen in
Figure 23.
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Figure 25. PVHSim1 and LSvVgat neurons reduce in activity during feeding bouts
(A-C) Activity of PVH and LSv neurons during feeding bouts. (A) Representative trace of
PVHSim1 neuronal population-level activity during feeding bouts. (B) Representative trace of

LSvVgat activity during a feeding bout. (C) Averaged neuronal activity overall for each neuronal
region compared to average during feeding bout (n=8 per group).
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Next, the PVH and LSv show tightly correlated activity levels during a variety of
anxiogenic stimuli from the environment (‘environmental cues’). As observed in Figure 26,
both the PVH and LSv respond to a sudden loud sound, a sudden shining of light in a dark
room, and water spray (this induced grooming). These observations indicate it is the
sudden anxiogenic stimulus and not grooming or a specific sensory modality driving the
activity. This feeds into a more general concept that the observed behaviors of feeding
and self-grooming and escape are not directly encoded by the LSv and DBB action, but
instead are readouts of the change in brain state. Indeed, the context- and intensitydependent intensity of expressed aversion, from self-grooming to escape activity, elicited
by the PVH-LS circuit indicates that the primary function of the LSv is as a gate, which,
when sufficiently activated, releases an action plan. That action plan is driven in this case
by the activity of the PVH.
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Figure 26. PVHSim1 and LSvVgat neurons increase in activity during various anxiogenic
environmental cues
(a-f) In vivo Ca2+ fiber photometry measurements of PVH and LSv neuron activity
during stress and feeding. Sim1-Cre (a, c, e, and g) and Vgat-Cre male mice (b, d, f, and h) with
AAV-FLEX-GCaMP6m delivery to the PVH (a, c, e, and g) or LSv (b, d, f, and h) were implanted
with optic fibers targeting the PVH or LSv for fiber photometry monitoring the in vivo activity of
PVH and LSv neurons in freely moving mice. A loud sound (a and b), a brief light exposure in
dark (c and d), water spray toward head (e and f) were associated with activation of PVH (a, c,
e, and g) and LSv (b, d, f, and h).
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Finally, we refined the GCaMP6-mediated monitoring of LSv-projecting PVH
neurons by using retrograde tracers, as described in section 3.3.2. The retrograde AAV
bearing a plasmid encoding cre, injected into the LSv with simultaneous injection of FLEXGCaMP6 into the PVH and placement of a fiber over this area, allows highly specific
monitoring of the PVHLSv-projecting neurons. This injection strategy can be seen in Figure
24C,D. In this setup, the PVHLSv-GCaMp6 neurons showed a similar set of responses as seen in
Figure 26, though the amplitude of response was less. Because of the numerous
differences between experimental conditions, it would be inappropriate to draw
conclusions about this difference in amplitude. However, what is clear is that the PVH LSvprojecting

neuronal activity is tightly correlated with anxiogenic environmental cues as seen

in Figure 27. This indicates the importance of this circuit for environmental monitoring.
Notably, in the same conditions, mice with PVH infection of FLEX-GFP instead of FLEXGCaMP6 showed no response to either water-spray or feeding bout
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Figure 27. LSv-projecting PVHGCaMP6 neurons are activated by anxiogenic cues and
inhibited by feeding
(a-f) In vivo Ca2+ fiber photometry measurements of LSv-projecting PVHGCaMP6 and
PVHGFP neurons during stress and feeding. (a-b) Comparison of amplitude of response to
water spray stimulus as described in section 2.2.6.3. in the (a) PVHGCaMP6 and (b) PVHGFP
animals. Grey traces indicate individual recordings and red represents the averaged response
(also for e). (c-d) Comparison of amplitude of response to initiation of feeding bout in mice
fasted for 12hrs, comparing the (c) PVH GCaMP6 condition and (d) PVHGFP condition. Grey is the
Ca2+ independent signal, and red is the dependent (e) Demonstration of PVHGCaMP6 neurons
responding to loud sound stimulus. (f) Comparison of the average %dF/F0 observed during a
feeding bout minus overall %dF/F0 in the PVHGCaMP6 and PVHGFP conditions (n=20 per
group, p<0.001)
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3.4.

Conclusions and Significance
In this study, we used the techniques refined in Chapter 2 to approach a previously

untested circuit projecting from the PVH to the LSv. What we found was that activation of
this circuit induced self-grooming and, at high intensities, fleeing behavior. Further,
activation prevented feeding in the fasted condition and the activation of the circuit was
aversive. Future work will need to demonstrate whether activation induces conditioned
place aversion. Notably, activation of a PVH Sim1-VTA neurocircuit studied in the Tong lab
does produce conditioned place aversion

385

. My work demonstrated that the PVH and LSv

both respond, in real-time, to a wide variety of anxiogenic environmental cues and are
suppressed by feeding behavior. Overall, this work represents a compelling parallel and
inversely functional circuit to the one I presented in Chapter 2 and provides new evidence
emphasizing the centrality of the hypothalamus in driving basal forebrain and septal
nuclei activity. This ties in quite nicely with data from our research showing that LH GABA
neurons inhibit PVHGlut neurons to cause feeding

, and converse evidence that the

286,294

LSvGABA neurons inhibit LHGABA neurons during feeding 386.
Notably, previous work from our own lab and others has not been able to elicit
such pronounced fleeing behavior by stimulation of PVHGlut projections to other regions,
such as the VTA
coeruleus

, nor PVHPDYN projections to the parabrachial nucleus or pre-locus

385

. Finally, the fact that the intensity of circuit stimulation determined the

387

progression from no response to self-grooming to jumping all show that the LSv is, at
baseline, 'preventing' these behaviors from emerging, until it is activated.
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This adds a unique piece of data to the concept suggested by Dr. Jeffrey Gray and
Neil McNaughton in their magnum opus, The neuropsychology of anxiety: an enquiry into
the functions of the septo-hippocampal system. In it, they claim that the septal nuclei act as
the filter of incoming alertness-inducing stimuli. During a period of behavioral inhibition,
these stimuli activate the PVH and the cortical sensory regions, but do not 'break through'
to the septal nuclei and their hippocampal targets until sufficient ascending signal
strength is attained

377

. This then causes the activation of hippocampally-encoded

memory-related responses to these alertness-inducing stimuli

310

. Optogenetic activation

of the presynaptic PVH neurons is sufficient to break through the filter, hence induce selfgrooming and fleeing behavior.
Overall, both from the perspective of improving our understanding of the basic
neurobiology of anxiety and fight-or-flight responses and from the perspective of
understanding human disease anew, this work is an important advance in the field. As
detailed above, the circuit has never before been functionally described and the detailed
analysis will allow further circuit mapping in the future.
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Chapter 4. Hypothalamic neurocircuits reciprocally controlling eating by
modulation of environmentally-driven anxiety
This chapter represents original review and concluding remarks produced for this
dissertation
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4.1. Eating, hunger, anxiety, and satiety: what do these words even mean?
The need for complexity.
Much of what is described in Chapters 2 and 3 was not possible to this degree of
resolution until the 21st century. The confluence of rapid advances in genomics, gene
editing, and protein engineering is responsible for the development of the tools
described above (Cre-loxp, viral vectors, ChR2, GCaMP6, etc). The primary benefit is the
cellular and molecular specificity in vivo that has heretofore been impossible; such
specificity in fiber photometry and calcium imaging are akin to the advances in patchclamp electrophysiology in the 1980s. However, this is in no way a negation of the
complex and rigorous neuroanatomical and behavioral work done prior to these
techniques. Limitation is substrate of creativity and often spurs lateral thinking and
paradigm-shifting conclusions. In my limited experience, perhaps because of the highly
technical nature of these advances requiring mastery of many diverse domains of
science, there has been some neglect in recent high-impact publications in neuroscience
of the more complex ideas developed in the 20th century, especially about behavior.
Further, although these techniques afford incredibly useful insights into cellular and
molecular characteristics of neurocircuits, there is a lack of subtlety in the interpretation
of the output behavior.
This is particularly apparent in my own field of the neuroscience of eating
behavior. The words hunger and satiety are easy to understand, but are extraordinarily
broad. Hunger is generally used to refer to the fact that, when given access to food, the
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animal eats the food. Satiety means that, when given access to the food, the animal does
not eat the food. As pure behavioral descriptions, that is sufficient, but from the
perspective of future translation of this information, they lack nuance. Further, emphasis
on the elicited behavior alone misses many more subtle findings that challenge the
participation of a particular nucleus in hunger or satiety.

4.2. Insights from the decerebrate rat on the challenges of interpreting
starvation, obesity, and simplified measures of hunger and satiety
Some examples of why these distinctions are important arise from experiments
with decerebrate animals, where the telencephalon and diencephalon have been
disconnected from the brainstem. This results in functional decerebration, where all
observed behavior is generated by the brainstem. Much of this work was performed by
Harvey Grill, Ralph Norgren, and others in the late 1970s and early 1980s. The technique
to produce a decerebrate rat is fairly simple though mechanically challenging to do safely:
after anesthesia, a spatula is inserted just rostral to the superior colliculi and pushed until
contact with the cranial floor is made, and sweeped left. A week later, the same is done to
the right; this staging helps prevent destruction of the superior sagittal sinus and cranial
nerves

388

. Completeness of transection was confirmed post mortem This results in

complete disconnection of the cortex, thalamus, and hypothalamus from the body.
Although such drastic surgery may seem more at home in The Island of Dr. Moreau by H.G.
Wells than a laboratory, it offered the following valuable observations.
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4.2.1. Aphagic and adipsic, but mobile with coordinated reactions to stimuli
As one may expect, decerebrate rats do not eat or drink and if left alone would
probably starve to death

389,390

. They were sustained by tube feedings. They also do not

have effective thermoregulation. The prime facie conclusion is that such extensive brain
damage prevents coordination of any sort of behavior. However, surprisingly, these
animals maintain a normal standing posture, groom spontaneously and correctly, and
have an intact acoustic startle reflex with pre-pulse inhibition

391

. While they don't move

spontaneously, they right themselves if turned over, squeak and run away if their paw is
pin-pricked, vigorously bite the pincher if their paws are pinched, and will jump out of a
cage and flee (with coordinated running) if their tail is pinched.

392,393

These responses

were all very exaggerated in intensity compared to controls.

4.2.2. Taste discrimination, hunger, and satiety without taste association
Intact rats have facial responses indicating "liking" and "disliking" food when
sucrose solution or sodium chloride versus quinine is placed on the tongue; further, they
will ingest and consume food or reject it by spitting it out

389

. This suite of behaviors is

collectively referred to as taste reactivity. Intraperitoneal injection of lithium chloride (LiCl)
causes a nausea response; pretreatment with LiCl before administering sucrose causes
the rat to reject sucrose taste on the next test, presumably because of the nausea
association. This suite of behaviors is referred to as bait shyness. Decerebrate rats have
the same taste reactivity as intact rats, but are not capable of developing bait shyness (i.e.
LiCl pairing did not affect subsequent feeding)

388

. This is in keeping with the absence of
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other sorts of classical conditioning such as to conditioned eye blink in the decerebrates.
In the same study, the experimenters pretreated intact and decerebrate rats with a tube
feeding. One hour later, administered sucrose solution every 5 seconds and monitored
taste reactivity, with 30 second breaks. This was compared to the 24hr and 48hr fasted
response. All fed rats initially accepted the solution, but eventually became satiated and
rejected further solution. In the fasted condition, they accepted far more volume of
solution before becoming satiated and rejecting. Increased sucrose concentration
increased the amount of solution accepted in both conditions.
Other work by Grill demonstrated that decerebrate rats also show normal
sympathetic control of gluconeogenesis. They injected 2-deoxy-D-glucose (2DG), a
competitive hexo/glucokinase inhibitor that mimics acute hypoglycemia, intraperitoneally
and thus elicited hyperglycemia in both decerebrates and controls (whereas saline did
not); however, the amplitude of response appeared to be slightly lower (average jump of
~100mg/dL compared to ~150mg/dL)

394

. There is some possibility, of course, that the

disconnected hypothalamus may still operate autonomously in response in changes to
the blood detected via the median eminence, and cause sympathetic response purely via
glucocorticoids.

4.2.3. An intact thalamus and hypothalamus restores voluntary locomotion
but disrupts normal grooming and makes all tastes aversive
Comparison to animals with a preserved thalamus is even more striking. The
surgery is more technical, requiring staged vacuum aspiration of the cerebral cortex,
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striatum, basal forebrain (stopping at the preoptic area), septum, and hippocampus.
Notably, the hypothalamus remains intact as well, but the shorthand nomenclature used
was a thalamic preparation and thalamic rats 390.
Thalamic rats are still aphagic and adipsic and lack thermoregulation. They had
most of the capabilities of the decerebrate rat. In addition, they spontaneously
locomoted; however when moving they held their head low, back arched, and 'tip-toed'
around. They had periods of quiescence and hyperactivity but overall were far more active
than control rats. Surprisingly, their grooming behavior was grossly impaired compared
to the decerebrate rat; their limbs would not make contact with the fur and over time they
became disheveled. Perhaps even more surprisingly, the thalamic rats responded to all
tastes as if they were quinine. The duration of the rejection response increased as the
concentration of all solutions increased. They rejected all fluid, including water, thus
making it impossible to test satiety.

4.2.4. Decerebrate and thalamic rat demonstrate the need to emphasize
acute, subtle behaviors, rather than only chronic state changes
The above information is surprising. Decerebrate rats do not engage in any goaloriented behaviors, but successfully engage in "housekeeping" ones (e.g. grooming,
attacking a threat, taste discrimination, differentiating hunger and satiety by rejecting
excess sucrose in the fed condition). Their responses are reflexive and intense. Thalamic
rats show some goal-oriented behavior (e.g. spontaneous exploration), but have
completely dysregulated housekeeping behavior and fail to successfully take in food. In
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both cases, careful investigation showed results opposite of what would be expected.
Although both rats would normally starve to death, the decerebrate rats (no
hypothalamus) show hunger, whereas the thalamic rats show an excess of satiety). The
conclusion varies wildly dependent on the level of readout.
Just as starvation here was not fully informative of whether the animal had a
deficit in energy intake due to excess satiety or lack of hunger, obesity is also not
necessarily informative of whether the animal has an excess of hunger or lack of satiety.
Work in the Tong lab has previously demonstrated that knockout of beta-receptor on
hematopoietic cells (primarily because of the loss of beta-receptor on the red blood cells)
is sufficient to enhance high-fat diet-induced weight gain over several weeks, despite the
fact that these mice consumed less food than controls. Sympathetic activation of the beta
receptors induced increased glucose consumption by the red blood cells, increasing the
animals’ total daily energy expenditure 395.

4.2.5. Hypothalamic nuclei are primarily involved in dis/inhibiting other brain
regions to release specific behaviors encoded by more primitive brain regions
As put by Garrett Stuber and Mark Rossi in the title of their 2018 review paper, all
of the above evidence really means is that there are Overlapping Brain Circuits for
Homeostatic and Hedonic Feeding

276

. Put another way, the fact that a given node elicits

feeding is probably more representative of the fact that it is generally disinhibiting or
activating the eating network subsequent to inhibition of some other network, and
ultimately behavior. This may explain why the decerebrate rats were capable of
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expressing hunger and satiety, whereas the thalamic rats were not; the former only
retained the brainstem circuits that directly control the spinal cord to evoke many of these
responses. The thalamic rats, by comparison, had several intact anxiety networks (such as
the PVH connections to the VTA and PAG), but did not have intact appetitive networks
(such as the VTA to nucleus accumbens - the latter was removed with the striatum). This
produced a profound imbalance, where all taste-related sensory information produced
the aversive response since it did not have a reciprocal, balanced appetitive network to
inhibit it.
This model, which views hypothalamic nuclei as being involved in generating or
inhibiting other areas to allow the release of particular behaviors, is akin to Jaak
Panksepp's concept of "affective states" and affective state competition that he has
reviewed extensively in many works 405–407. The utility of this model is it helps provide
much more nuance and meaning to the vast array of behaviors elicited by optogenetics
and observed by fiber photometry, and it calls for greater emphasis on the subtle
differences in behavior observed during a given experiment, rather than a focus on
chronic effects. Any given brain region has a unique set of inputs and outputs - however,
there are common networks between them that ultimately allow release of a brainstem
behavior. The medial forebrain bundle is a good example of this, as it clearly connects the
disparate subcortical brain regions involved in what Panksepp would call the affective
state of "seeking" i.e. willingness to explore and consume previously unknown substances
and learn their properties. The VTA seems to be primarily responsible for the locomotive
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and learning aspects of the "seeking" affective state; the lateral hypothalamus seems to
be responsible for the consummatory aspects of the "seeking" affective state 304,306,396.

4.3. A proposed wiring diagram: LH GABA neurons inhibit multiple nodes in
the PVH anxiety network to promote consumption
Obviously, the "seeking" affective state described above is a high level abstraction.
Likely, such affective states and their underlying networks are determined by much more
than just physical location (e.g. molecular characteristics and firing frequencies). Further,
because of the current lack of nuance involved in distinguishing behaviors elicited by
specific projections, so far only a small number of distinct affective states have been
elucidated. For example, many researchers consolidate brain states to what are easily
called appetition and aversion, formulated by William Craig over 100 years ago

397

. When

these behaviors are not-goal directed, they have default outputs that can, for simplicity's
sake, be called consumption and anxiety. Yet, this makes understanding the wiring
diagrams of several nuclei more intelligible - rather than any projection mediating a
necessary part of the seeking response itself, for example, it may instead be dampening
or enhancing the activity of another structure.
It is in this framework that I have integrated the data presented here with other
neurocircuit research into Figure 28

286,311,373,386,398–401

. What this demonstrates is that the

LHGABA and PVHGlut nodes are are pretty clearly parallel to each other and drive opposite
behaviors (consumption and anxiety). Whereas, the basal forebrain seems to be
responsible for driving environment specific behaviors. This is in keeping with my findings
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in Chapter 2 - the LH actively suppresses environment-driven responses in order to allow
feeding to occur. Conversely, as in Chapter 3 activation of the PVH-LSv circuit causes nonspecific fleeing behavior, regardless of the environment (e.g. intruder assay).
There is, of course, an incredible amount of complexity that is not conveyed in this
wiring diagram - it is not meant to be exhaustive, but instead demonstrate the
"competing states" theory. The LH GABA neurons are the only projections within this
network that drive non-specific feeding, and the PVH projections conversely only drive
non-specific anxiety. Although the medial and lateral septum projections to the LH were
demonstrated to prevent feeding behavior 386,398 , unfortunately those publications did not
evaluate any other behavior for the specific projection, even though it appears the
diagonal band and septal nuclei are particularly context dependent in their control of
behavior.
Figure 28 also emphasizes the basal forebrain's role as a "selector" of environment
specific responses once either the consumption or anxiety response has been generated,
via mechanisms beyond its classical interaction with the hippocampus

313

. For example,

activation of the ventral-basal forebrain somatostatin projections to the LH causes specific
consumption of fat, but not sucrose 372. Activation of the DBB glutamatergic projections to
the LH causes selective avoidance of food stimuli, but not general anxiety

373

. Perhaps

most interestingly, activation of the local MS-DBB glutamatergic projections to the
GABAergic septal neurons does not produce any behaviors (at least that have been
published), but enhanced the signal strength of locomotion-induced theta rhythms in the
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hippocampus

311

. In other tests, the septum-driven hippocampal theta rhythm is

associated with multiple types of anxiety-related behaviors; further, there is a
hippocampus glutamate -> LH glutamate circuit that also causes non-specific anxiety
402,403

. These observations add another network loop to the interrelationship between

eating, anxiety, and responsiveness to the environment. Further, it should also be clear
that there is great potential for the LH, which is activated by the mere act of eating food
296,309,400,404

, to inhibit anxiety driven by environmental cues (encoded by the basal

forebrain-septal nuclei - hippocampus loop) .
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Figure 28. A network diagram of competing consumption and anxiety circuits
within the LH, PVH, and basal forebrain
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4.4.

Summary and limitations
This dissertation began with describing the sobering reality that there has been

unchecked explosion in metabesity in the United States. It ends with a wiring diagram
relating neurocircuits inducing non-specific consumption and non-specific anxiety to
those that drive context-specific behaviors. What is the connection? It appears to me the
common view in the medical field that the reason people develop metabesity arises from
one of three factors:
1. Completely external loci of control unrelated to behavior: genetics, reduced basal
energy expenditure, specific disruption of peripheral homeostatic mechanisms
2. Impaired ratio of sensitivity to peripheral hunger signals (e.g. ghrelin) to satiety
signals (leptin) drives irresistible eating
3. Dopaminergic-opioid (i.e. rewarding) drives eating of food in a non-hunger
circumstance.
Certainly, there is robust and valuable evidence that warrants this focus. In mice,
altering any of these knobs produces profound changes in hunger, satiety, obesity, and
starvation. In humans, manipulating these variables also has acute effects. Yet, they
rarely have lasting success. I believe this is not because these mechanisms are irrelevant
in humans (clearly they are, as a few individuals do have great response), but because any
success in one area is overridden by failure to treat another underlying driver of eating.
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Put another way, manipulation of these mechanisms is necessary, but not sufficient to
reliably produce sustained weight loss.
In this work, I have presented two circuits showing reciprocity between systems
that suppress eating (PVH glutamate) and activate with eating (LH GABA). They inhibit
each other. These are part of broader networks that produce distinct affective states (here
referred to as non-specific anxiety and non-specific consumption). Combined with the fact
that the LHGABA consummatory network is activated by food consumption, rather than
hunger per se, it appears that this circuit may be intentionally exploitable. This
exploitation manifests as ‘stress eating’, i.e. eating when one is not hungry nor
particularly desirous of specific foods in order to reduce the sensation of stress/anxiety
originating from these other networks. This is similar to self-medication with
dopaminergic drugs observed clinically in depressed individuals.

4.4.1. Limitations
It is crucial to discuss the limitations of the techniques used in this study. First,
many of the techniques utilized, though powerful, have substantial drawbacks. The
genetically modified mice are an inbred strain, and although widely used within the fields
of optogenetics and calcium imaging, may have substantial differences in their baseline
behavior and response to manipulations compared even to other mice. It is increasingly
understood that these inter-strain differences are particularly pronounced in behavior
. Thus, this caveat must be kept in mind while interpreting the translatability of

338,350,405,406

any of these findings.
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Second, all of the animal models used relied upon neurosurgically delivered viral
vectors to deliver the gene encoding Cre-dependent ChR2, GCaMP6, etc. to the region of
interest. All of the Cre lines used, except Sim1-Cre in Chapter 3, had Cre expression in offtarget areas immediately adjacent to the region of interest (Vgat-Cre in the LH and DMH
and zona incerta, Pdx1-Cre in the LH and DMH, Vglut2-Cre in the PVH and VMH, etc.).
Although injection sites were verified, and in my subjective observation the few ‘misses’
that were excluded did not appear to show any photostimulation-related behavior, it is
still very important to consider that these adjacent regions also may contribute to these
findings.

Unfortunately,

as

discussed

in

Section

2.1.,

the

hypothalamus

has

extraordinarily high cell-type heterogeneity. It appears that the basic developmental and
neuroanatomical

principles

responsible

for

coordinating

these

regions’

circuit

participation requires much more research before such targeting techniques can be used.
Although monosynaptic retrograde infection of presynaptic partners, as seen in the retroAAV2 tracing experiment (Figure 8), can help increase the presynaptic specification to
some degree, the technology still needs some improvement in order to allow full
molecular specification both pre- and postsynaptically.
It is likely that the next few years will show extremely clever combination of Creloxp and Flp-frt (a system similar to Cre-loxp but with no crossover) systems to overcome
these issues 407. For example, in a Vgat-Flp animal, the postsynaptic region can be infected
with retroAAV2-Cre, and the presynaptic region with DIO(Cre)-DIO(Flp)-ChR2. This plasmid
requires both Cre excision AND Flp excision before it will be expressed, thus allowing only
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presynaptic GABAergic neurons to be activated. Another example of use of this dual
recombinase system is cell-fate mapping, such as examining a cross between ChAT-Cre
and Vglut2-Flp in a mouse with Flp-dependent and Cre-dependent reporters 408.
Third, the natural limitation of any behavioral neuroscience endeavor is the
difficulty in assessing the internal experience of the mouse. Mice cannot verbally
communicate their experience, which limits correlation with human experience. Thus,
there inherently is a substantial risk for either over-interpretation of the behaviors seen in
a form of anthropomorphization, or an insufficient degree of attention paid to animal
behavior, losing important subtle differences that would be easy to see in a human. In
psychology, this problem is often discussed as the ‘face validity’ of the questions asked in
a test to the actual experience they are attempting to capture. An excellent review of the
challenges of face validity in rodent models of human psychiatric diseases can be found
here 409.
My work described above certainly suffers from these limitations and the question
of face validity. It is not possible yet to be certain how translatable these findings are to
humans. Future work with humans in ethologically relevant conditions is necessary
before conclusions on the interrelationship between anxiety and hunger as humans
experience and express these affects. The next two sections will discus what data does
exist with regards to the translation of rodent behavioral findings to human behavioral
findings.

163

4.4.2. The evidence supporting translation of rodent behavior to human
behavior
It is worth asking directly: is it valid to compare human and rodent behavior at all?
Is it reasonable to infer internal experience from external behavior? On these points, I
agree with Panksepp’s discussion of this problem and his conclusion that when human
and mice exhibit similar stereotyped mammalian behaviors (e.g. facial expressions in
response to pain, eating, etc.), their internal experience, variously described as affect,
emotion, or consciousness is also similar

410,411

. This conclusion is derived from several

observations. The subcortical neuroanatomical organization of the mouse brain and
human brain are similar, both in structure and in gene expression patterns during
development – though obviously this is a generalization and a few subcortical areas are
organized differently

412,413

. Further, electrode stimulation of mouse and human

subcortical regions like the median forebrain bundle, as demonstrated by intracranial
self-stimulation (ICSS) studies performed in the 1950s and 60s, produce similar rewardseeking behaviors

414–416

. Finally, the primary difference between human and mouse

neuroanatomy arises from the expansion of the neocortex; damage to neocortical tissue
in humans does not appear to alter the quality of affective experiences, but instead
reduces the ability to regulate their expression. Evidence from patients with traumatic
brain injury to the frontal lobe and frontotemporal dementia are demonstrative of this
point

417–420

. Thus, it is reasonable to assume that manipulation of mouse subcortical

tissue produces affective states similar to those experienced by humans. The translation
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becomes more difficult once regions associated with cognition, like the prefrontal cortex
and frontal cortex, are involved.
All of this being said, the analysis of mouse behavior and correlation of that to
human experience still remains quite limited. One problem is the relative paucity of
human-to-mouse translatable behavioral tests; because of the complex and rich
information that is possible to derive from verbal report, it appears few studies observe
human behavior absent communication.

4.4.3. Recent human experiments that replicate rodent behavior and a call
for further validation and ‘human-to-rodent’ translation
There are several recent high quality and highly informative studies that have
attempted to replicate rodent studies of affective states in humans directly

421

. One such

study examined human exploratory behavior by tracking subjects with a GPS as they
explored a central city area (a sort of natural open field test with clear boundaries and
open areas)

422

. Four groups were tested in two comparisons: subjects diagnosed with

agoraphobia compared to healthy controls; and subjects with no previous diagnosis who
scored as high anxiety sensitivity versus low anxiety sensitivity on a validated scale for
anxiety. The agoraphobic subjects and high anxiety sensitivity groups both showed a
significantly reduced level of exploration of open areas compared to the controls. This
correlates nicely with the open field test in rodent research, where a greater degree of
avoidance of the center is described as increased levels of anxiety.
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In another experiment, the influence of anxiety and pharmacological manipulation
on open-arm exploration of an elevated plus maze (EPM) was tested

423

. Facilitated by the

recent development of immersive virtual reality technology, humans evaluated to have
high basal anxiety showed reduced exploration of the open arm of the EPM. The high
anxiety humans, as compared to the low anxiety humans, also had higher peak
concentrations of salivary alpha-amylase and salivary cortisol as well as increased heart
rate, respiratory rate, and skin conductance in the immediate post-test period.
Administration of lorazepam (a benzodiazepine anxiolytic) in a placebo controlled,
randomized and double-blinded study significantly 1) reduced the latency to first open
arm visit and 2) increased the amount of time spent on the open arm of the EPM as
compared to placebo. By comparison, administration of yohimbe, a sympathomimetic
anxiogenic drug had the exact opposite effects. The self-reported levels of anxiety were
also reduced or enhanced by these drugs, respectively. The findings of this study
correlate well with the assumptions made about the meanings of open-arm avoidance in
the EPM in rodent behavioral neuroscience.
Behavioral observations of human infants also offer some insights into the basic
nature of hunger and taste preference in humans, while avoiding the complexity
associated with verbal report. When presented with sweet (sucrose) and bitter (quinine)
solutions, they produce similar facial expression for liking and aversion as the
decerebrated rats 424. Further, several food neophobia (fear of new food) scales have been
developed and tested in humans during food choice assays

425

. Although evidence is
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limited, it appears that pathological manifestations of food neophobia – selective eating
in children significant enough to lead to malnutrition – correlate with generalized anxiety
375,426

. This has some adjacency to the data discussed here, as latency to initiation of

feeding behavior has been used as the metric of rodent neophobia and by proxy, a
measure of general anxiety 369.
It appears promising that many of the findings in rodent behavioral neuroscience
may translate to humans, and vice versa. Particularly with recent technological
advancements in virtual reality and human behavior tracking, a widely expanded
psychoactive pharmacological armamentarium, and non-invasive neurostimulation, it is
becoming increasingly feasible to directly probe human neurocircuits and their behavioral
outputs in tightly-controlled experiments. However, most of the behavioral tests
performed in Chapters 2 and 3 have no validation in humans yet. Thus, the translation of
their findings is limited. However, there is great opportunity to work on the
interrelationship of human and rodent behavior and subsequently translate rodent
findings with complex manipulations as described here, to human behavior and human
disease.

4.5.

Conclusion
The goal of this work has been to bring new appreciation to the role of the

hypothalamus in mediating the interaction between affective states, with special
reference to how hunger and its associated eating behavior may suppress negative
affects like anxiety, and vice versa. Further, it has aimed to pose the hypothesis that
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intentional manipulation of these eating neurocircuits to suppress anxiety is a potential
driver of the epidemic of metabesity, similar in nature to how intentional manipulation of
the endogenous reward neurocircuitry by use of substances of abuse was found to
explain many aspects of addictions.
It is my hope that future work will elaborate on the LH-DBB and PVH-LS with
greater nuance and more complex tests of behavior. There is now abundant technology,
improving every year in specificity and sensitivity, to tackle challenging questions about
the neurocircuits undergirding affective states and their interaction with each other.
Similarly, it is now possible to perform similar experiments validating these behavioral
findings in humans. My prediction is that eating will prove to be a potent suppressor of
negative affective states like anxiety and stress both in rodents and in humans and that
this effect relies upon hypothalamic neurocircuits, including the LH-DBB. Further, I predict
that a behavioral and pharmacological treatment regimen directly targeting daily stress
and anxiety, combined with existing dietary strategies and satiety pharmacology
discussed in Chapter 1, will prove to be effective in treating metabesity.
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